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ABSTRACT 
Nicholas C. Kappas: Analysis of the VEGFR1 (FLT-1) isoforms  
in vascular development 
(Under the direction of Victoria L. Bautch) 
 
While sprouting angiogenesis is critical to blood vessel formation, the cellular 
and molecular controls of this process are poorly understood.  As blood vessels 
form, the endothelial cells that comprise the vessel must coordinate the processes of 
cell division and cell migration for proper vascular morphogenesis to occur.  
Vascular endothelial growth factor-A (VEGF-A), an endothelial cell-specific ligand, is 
critical for these endothelial cell responses.  Two high affinity receptors for VEGF-A, 
Flk-1 and Flt-1, are responsible for the effects of VEGF-A on vascular development.  
While VEGF-A signaling through Flk-1 has been shown to stimulate endothelial cell 
division, migration, and survival, the role of Flt-1 is less clear. Mice lacking the flt-1 
receptor die around mid-gestation (E9.5) due to vascular overgrowth and 
disorganization.  It is thought that Flt-1 acts to sequester VEGF-A, thereby inhibiting 
signaling through Flk-1. 
In my thesis work, I have used time-lapse imaging of GFP-expressing vessels 
derived from mouse embryonic stem (ES) cells, to reveal a role for flt-1 in 
modulating vascular branch (sprouts) formation and migration.  Analysis of time-
lapse data also reveals that flt-1 mutant vessels have increased rates of endothelial 
 iii
cell division.  This data supports a model whereby the role of flt-1 is to positively 
regulate sprout formation and migration and negatively regulate endothelial cell 
proliferation. 
Flt-1 is expressed as a full-length receptor tyrosine kinase (mFlt-1) and as a 
soluble isoform (sFlt-1).  In order to get a clearer understanding of the role of the flt-1 
isoforms in vascular development, I have reintroduced each flt-1 isoform into flt-1 
mutant ES cells.  My results reveal that the sFlt-1 isoform rescues the vessel 
branching morphogenesis defect observed in flt-1 mutant vessels, and that it does 
so more efficiently than the mFlt-1 isoform.  Furthermore, both flt-1 isoforms appear 
to partially rescue the cell proliferation defect.  These results support a model 
whereby Flt-1 primarily affects vascular branching morphogenesis via a soluble 
molecule, sFlt-1, perhaps by affecting the formation of a VEGF-A gradient that 
normally provides directional information for sprouts.  These results also reveal that 
both Flt-1 isoforms have the ability to regulate endothelial cell proliferation.   
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CHAPTER I 
 
GENERAL INTRODUCTION 
 
 
In this thesis, I describe my work investigating the role of the VEGF-A 
receptor, flt-1, in murine blood vessel development.  Specifically, chapter II 
describes time-lapse imaging of wild-type and flt-1 mutant ES cell-derived blood 
vessels.  This analysis has revealed both dynamic processes of normal blood vessel 
development along with morphogenetic and cell division defects in the development 
of flt-1 mutant blood vessels.  Chapter III investigates the role of the two flt-1 
receptor isoforms, soluble flt-1 (sflt-1) and membrane-tethered flt-1 (mflt-1), during 
vascular development.  Here, I have demonstrated that sflt-1 is more efficient than 
mflt-1 in rescuing a flt-1-/- morphogenesis defect, while both isoforms can affect a 
rescue of endothelial cell proliferation.  This work supports a model whereby flt-1 
primarily affects vascular branching morphogenesis via a soluble molecule, sflt-1.  
Chapter IV describes the relationship between endothelial cell division and vascular 
branching morphogenesis.  I begin with a general introduction on vascular 
development, followed by what is currently known about how flt-1 exerts its effects 
on vascular development. 
 
A.  Mechanisms of Blood Vessel Formation 
 
The basic constituents of the vascular system, endothelial and blood cells, 
are determined very early during embryonic development in vertebrates (Flamme et 
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al., 1997; Olsson et al., 2006; Risau and Flamme, 1995).  The closed circulatory 
system is critical for promoting cellular survival and growth by functioning as a 
transport system for nutrient distribution, gas exchange, and waste removal to 
essentially all tissues of the body.  This is highlighted by the fact that the 
cardiovascular system is the first functional organ that develops in the vertebrate 
embryo.  Early vertebrate embryonic life relies on passive diffusion to facilitate 
oxygen uptake.  However, as the size of the embryo increases, passive diffusion is 
not an effective method of gas exchange.  The increasing oxygen demands of the 
embryo are met by induction of the cardiovascular system, whereby formation of the 
heart, blood, and blood vessels are initiated. 
 The initial steps of blood vessel formation require a combination of multiple 
cellular processes in several cell types to form a mature, branched vascular network.  
The first steps in developing a primitive branched vascular plexus involve 
differentiation, migration, cell division, and fusion of endothelial cells.  This nascent 
plexus subsequently matures and strengthens by recruitment of mural cells, such as 
smooth muscle cells and pericytes, which envelop the primitive endothelial cell 
vessel lining.  In the mouse, the vascular network is connected to the developing 
heart, and circulation is established upon initiation of the heartbeat around 
embryonic day 8.5 (E8.5) (Nishii and Shibata, 2006).  
 During development, blood vessels form through a combination of two 
processes termed vasculogenesis and angiogenesis (Noden, 1989) review: (Risau, 
1997).  Vasculogenesis is the in situ differentiation of endothelial cells from 
mesoderm, and the subsequent coalescence of these endothelial cells into a 
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primitive cord (Risau and Flamme, 1995).  Angiogenesis is the subsequent 
expansion of blood vessels from a pre-existing primitive cord or blood vessel, by 
both sprouting and non-sprouting mechanisms (review) (Risau, 1997).  Blood 
vessels are then pruned and remodeled into a functional adult circulatory system.   
 
1.  Vasculogenesis 
 The first step in the process of vasculogenesis involves the differentiation of 
endothelial precursor cells known as angioblasts.  Angioblasts differentiate from 
multiple mesodermal sources, such as from lateral-plate, paraxial, and yolk sac 
mesoderm around embryonic day 7.0 (E7.0) of mouse development (Coffin et al., 
1991; Risau and Flamme, 1995).  Several key experiments have suggested crucial 
roles for fibroblast growth factor (FGFs) and bone morphogenetic proteins (BMPs) 
as inductive cues for the angioblast lineage.  Dissociated quail epiblast can be 
induced to form both endothelial cells and hematopoietic cells upon treatment with 
FGF (Flamme and Risau, 1992).  Also, the use of endothelial cell markers in 
conjunction with lineage tracing suggest the requirement of BMP signaling in 
hematopoietic and endothelial cell development (Walmsley et al., 2002).  The first 
secreted molecule with specificity for the endothelium during development is 
vascular endothelial growth factor (VEGF).  Angioblasts express markers such as 
the VEGF receptors Flk-1 (VEGFR-2) and Flt-1 (VEGFR-1), as well as PECAM 
(CD31) (Bautch et al., 2000; Drake, 2003; Fong et al., 1996; Yamaguchi et al., 1993) 
following their specification.  Subsequent morphogenesis transforms vessel cords 
into lumenized vessels, and by this time, angioblasts begin to express more 
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definitive endothelial cell markers such as CD34, VE-Cadherin, and ICAM-2 (Bautch 
et al., 2000; Drake and Fleming, 2000; Kamei et al., 2006).   
 Expression of many of the aforementioned markers is not unique to the 
endothelial cell lineage, since some hematopoietic precursors and other cell types 
also express these markers.  However, as with the hematopoietic lineage, a set of 
markers defines the endothelial cell lineage.  The expression of markers by both 
endothelial and hematopoietic cells, in addition to the observation that close 
association of nascent endothelial cells with blood cells occurs in the blood islands 
of the yolk sac, has led to the hypothesis that both of these cell populations are 
derived from a common precursor, known as the hemangioblast (Sabin, 1920); 
Murray, 1932; His, 1990; (Choi, 2002).  The hemangioblast model was further 
supported by the isolation of individual genes that, when mutated, affected the 
development of both endothelial and hematopoietic lineages (Carmeliet et al., 1996; 
Damert, 2002; Ferrara et al., 1996; Shalaby et al., 1995).  Further evidence for the 
existence of the hemangioblast was found with the isolation of individual cells that 
can differentiate into both blood cells and endothelial cells from embryonic stem (ES) 
cell cultures (Choi et al., 1998; Wang et al., 2004).  Additional studies provide 
evidence for the existence of hemangioblasts.  In vitro experiments identify a 
postnatal hemangioblast in a subset of cells that express CD34, a marker for 
hematopoietic progenitors, and Flk-1 (Pelosi et al., 2002) .  There is also evidence 
that hemangioblasts arise from cells that express the TEK receptor in the aorta-
gonad-mesonephros region of the mouse (Hamaguchi et al., 1999).  Furthermore, 
hemangioblast commitment has recently been demonstrated to arise from the 
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murine primitive streak, before blood island development occurs in the yolk sac 
(Huber et al., 2004).  These results suggest that angioblasts can derive from a 
hemangioblast precursor; however, it has been suggested that the hemangioblast is 
not a required intermediate.  An example of this can be found in the dorsal aorta, 
which assembles in the absence of hematopoiesis (Jaffredo et al., 2000).  
 Once angioblasts coalesce (by either migratory or non-migratory 
mechanisms) and differentiate to form endothelial cells, these primitive vessels can 
then become lumenized.  Subsequent expansion of a lumenized vascular network is 
required for establishing the circulation of blood in the embryo. 
 
2.  Angiogenesis 
 During angiogenesis, primitive vessels that form by vasculogenesis expand to 
form secondary vascular segments such as capillaries and venules (Olsson et al., 
2006; Risau, 1997).  There are two types of angiogenesis in vivo, they are termed 
sprouting and non-sprouting (intussusceptive) angiogenesis (Burri, 1992; Burri and 
Tarek, 1990). 
 During development, sprouting angiogenesis occurs in both the embryo and 
in the yolk sac when vessels sprout from an established parent vessel.  The 
sprouting of new vessels follows a well-defined program that includes proteolytic 
degradation of the basement membrane, endothelial cell proliferation, formation of 
solid sprouts of endothelial cells connecting to a neighboring vessel via cell 
migration, and restructuring of a sprout into a lumen, lined by endothelial cells and 
integrated in the vascular network (Ausprunk and Folkman, 1977; Burri et al., 2004; 
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Clark and Clark, 1939; Daniel and Abrahamson, 2000).  In the embryo, the 
intersomitic vessels, which branch from the dorsal aorta, form by sprouting 
angiogenesis.  Also, the brain is vascularized by the process of sprouting 
angiogenesis. 
 In the process of non-sprouting angiogenesis, a pre-existing vessel is split 
into two by localized extracellular matrix and tissue invasion.  This was first 
demonstrated in capillary beds of the lung, where intussusception predominates 
over sprouting angiogenesis (Burri, 1992).  During development, non-sprouting 
angiogenesis occurs simultaneously with sprouting angiogenesis. 
Although vasculogenesis and angiogenesis are often times thought of as 
occurring during two different stages of development, where vasculogenesis occurs 
early during development, and angiogenesis vascularizes most embryonic organs 
and all adult blood vessels.  However, there is evidence that endothelial precursor 
cells may contribute to neoangiogenesis in the adult, suggesting that both 
vasculogenesis and angiogenesis may be functioning throughout life (Asahara et al., 
1997). 
Once the vascular endothelium has assembled, mural cells such as smooth 
muscle cells (SMCs) and pericytes are recruited to the vascular endothelium to 
provide structural support.   SMCs and pericytes are important regulators of blood 
vessel development, maturation, and remodeling (review) (Eklund and Olsen, 2006).  
Angiopoietin-1 and 2 (Ang1 and Ang2), which are expressed by pericytes/SMCs and 
endothelial cells, respectively (Maisonpierre et al., 1997), have also been identified 
as ligands for the receptor tyrosine kinase, Tie-2 (Davis et al., 1994).  Signaling 
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through the endothelial cell-specific receptor, Tie-2, is important for endothelial cell 
survival, vascular permeability, and may regulate recruitment of pericyte/SMC to the 
vascular endothelium.  Ang1 signaling through Tie-2 has been shown to function in a 
complementary and coordinated fashion with VEGF-A, and contribute to 
angiogenesis and the maturation and stabilization of blood vessels (Sato et al., 
1995) (Suri et al., 1996).  Targeted mutation of Tie-2 or Ang1 in mice results in 
embryonic lethality between day 9.5 and 12.5 due to a lack of remodeling of the 
primary capillary plexus (Sato et al., 1995) (Suri et al., 1996).  Thus suggesting a 
requirement for proper maintenance and remodeling of the vasculature in the 
embryo and adult.  
 
3.  Blood Vessel Formation in the Adult 
 Although it is established that blood vessels form and expand during 
development, angiogenesis can also occur in adult vertebrates.  The formation of 
new vessels in the adult is essential when there is vessel occlusion, and the body 
must form collateral vessels to bypass the ischemic area.  Vascular sprouting is also 
essential during wound healing (Folkman and Klagsbrun, 1987).  Moreover, adult 
angiogenesis is also at play during a variety of pathological conditions such as 
diabetic retinopathy, arthritis, and tumor formation (Folkman, 2003; Frank, 2004).   
 Although there are other mechanisms of adult angiogenesis, one model 
involves the recruitment of new vessels to hypoxic tissues.  VEGF expression is 
regulated by oxygen, and most cells secrete VEGF when they experience hypoxic 
conditions, resulting in the directional growth of vessels to the hypoxic tissue.  
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Adaptation to hypoxic conditions involves changes in the protein expression and 
DNA binding activity of a family of transcription factors known as hypoxia inducible 
factors (HIFs), the most prevalent form being HIF-1α, which can directly promote 
VEGF expression (Brahimi-Horn and Pouyssegur, 2005).  Thus, to recruit these 
vessels, hypoxic tissues can secrete pro-angiogenic growth factors such as VEGF to 
invade tissue and supply needed oxygen and nutrients (Maxwell and Ratcliffe, 
2002). 
 The microenvironment of tumors is a good example of the hypoxic model of 
adult angiogenesis.  As tumor cells proliferate, they will typically outgrow their 
vascular supply, leading to the formation of hypoxic tumor cells that are thought to 
be sensed by the vascular supply (review) (Verma, 2006).  Tumor tissues 
subsequently secrete VEGF, which leads to the recruitment of host-derived blood 
vessels (Carmeliet, 2005).  These newly recruited blood vessels provide cancerous 
cells with the nutrients and oxygen necessary for growth and survival, while also 
providing a mechanism for metastatic cells to migrate to other regions of the body, 
where they can reinitiate de novo tumorigenesis.   
 
4.  In Vitro Differentiation of Embryonic Stem Cells to Form Vessels 
 While the mouse is a powerful genetic tool and model system to examine 
both embryonic and adult blood vessel formation, mice have the disadvantage that 
development occurs in utero and it is not easily accessible for manipulation. Also, 
because embryonic lethal phenotypes make it virtually impossible to examine 
subsequent vascular phenotypes, embryonic stem (ES) cells provide a useful 
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method to study certain aspects of blood vessel development (Bautch et al., 1996; 
Wang et al., 1992).   
 Embryonic stem (ES) cells, which are derived from developing mouse 
blastocysts, have the capacity to give rise to all cell types in the adult body.  The 
ability of ES cells to do so has opened the door for novel experimental approaches 
in the field of developmental biology.  Under appropriate culture conditions, ES cells 
will also differentiate and form embryoid bodies (EBs).  Upon attachment to a 
permissive surface, EBs continue a programmed differentiation, where many of the 
cells that differentiate from the EB in vitro reflect those found in the developing 
embryo and yolk sac, such as hematopoietic cells, endoderm, and endothelial cells 
(Bautch, 2002; Wang et al., 1992; Wiles and Keller, 1991).  The ES culture system 
has been used as a model to study blood vessel formation in flt-1-/-, flk-1-/-, and 
vegf-a-/- genetic backgrounds (Bautch et al., 2000; Kearney et al., 2002; Kearney et 
al., 2004; Schuh et al., 1999).  Endothelial cells that arise during ES cell 
differentiation have the potential to form primitive blood vessels, comparable to the 
vessels that first form in vivo, further suggesting that endothelial cell differentiation in 
this model system mimics the in vivo environment (Bautch, 2002; Bautch et al., 
2000; Kearney et al., 2002). 
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B.  Molecular Control of Blood Vessel Development 
 Many of the genes that are essential for the proper development of blood 
vessels have already been identified.  Vascular Endothelial Growth Factor-A (VEGF-
A), VEGFR-2 (Flk-1) and basic Fibroblast Growth Factor (bFGF) are thought to 
influence angioblast differentiation (Carmeliet et al., 1996; Ferrara, 1999; Ferrara et 
al., 1996; Shalaby et al., 1997). 
Correct modulation of VEGF-A signaling via Flk-1 is required for proper cell 
division and migration of endothelial cells during blood vessel formation, and it is 
thought that Flt-1 is a negative regulator of Flk-1 signaling (Kearney et al., 2002; 
Roberts et al., 2004). In the next section, I will discuss several of the molecules that 
modulate vascular development.  I will begin with a discussion of VEGF-A, and 
follow with discussion of the VEGF-A receptors, Flk-1 and Flt-1.  These molecules 
comprise a signaling transduction pathway that regulates cell migration, division, and 
survival, and is essential for proper vascular development (Ferrara and Davis-
Smyth, 1997; Shibuya et al., 1999). 
 
1.  Vascular Endothelial Growth Factor-A (VEGF-A) 
 The VEGF family members are part of the PDGF growth factor family of 
proteins.   Although VEGF-A is the family member most extensively studied, there 
are five total members that make up the VEGF family (VEGF A-D, PLGF).  VEGF-A 
was originally discovered as an efficient and rapid inducer of vascular permeability in 
vivo (Keck et al., 1989) and therefore is also known as vascular permeability factor 
(VPF).  VEGF-A is secreted from non-endothelial cells and preferentially forms 
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homodimers, although VEGF-A and PLGF heterodimers have been identified (De 
Falco et al., 2002).  Most biological activities of VEGF-A are mediated by its 
interaction with two high-affinity receptor tyrosine kinases, Flt-1 and Flk-1, which are 
expressed on endothelial cells.  In vitro studies have indicated that VEGF-A 
stimulates endothelial cell migration, division, and survival (Bernatchez et al., 1999; 
Gerber et al., 1999; Leung et al., 1989).  Gene targeting studies have also shed light 
on the role of VEGF-A, demonstrated by an experiment in which genetic deletion of 
only a single copy of VEGF-A results in embryonic lethality at mid-gestation (E11) in 
mice due to severe defects in vasculogenesis and angiogenic sprouting (Carmeliet 
et al., 1996; Ferrara et al., 1996).  Moreover, further analysis revealed that VEGF-A 
homozygous null mice, generated by aggregation of mutant ES cells with tetraploid 
embryos, also resulted in embryonic lethality around E9.5-E10, due to severe 
defects in vascular development.  Furthermore, two-fold overexpression of VEGF-A 
led to embryonic lethality in mice (Miquerol et al., 2000).  Likewise, analysis of blood 
vessel formation from VEGF-A+/- and VEGF-A-/- ES cell cultures (Bautch et al., 
2000) demonstrates a dose-dependent requirement for VEGF-A in vascular 
development.   
 Murine VEGF-A is transcribed from a single gene that is alternatively spliced 
to form three mRNA species, encoding three proteins: VEGF120, VEGF165, and 
VEGF188 (Ng et al., 2001a; Shima et al., 1996; Tischer et al., 1991).  These isoforms 
have differing affinities for heparin sulfate proteoglycans, and therefore are predicted 
to be distributed differentially from VEGF-A-producing cells via differential binding to 
the extracellular matrix.  VEGF120, which lacks a heparin binding domain, is thought 
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to be diffusible.  VEGF188 contains two heparin-binding domains, and is thought to 
be found on the cell surface or bound to the extracellular matrix in close proximity to 
the VEGF-A producing cell.  VEGF165, which lacks one of the two heparin-binding 
domains, is thought to have intermediate properties (Park et al., 1993).  Thus, a 
model has been proposed in which the VEGF-A isoforms establish a morphogen 
gradient, and that an intact gradient is crucial for proper vessel formation and 
patterning (Ruhrberg et al., 2002; Stalmans et al., 2002).  In support of this model, 
analysis of retinal vessels of mouse mutants expressing only VEGF120 or VEGF188 
showed defects in vessel size and number, suggesting that proper VEGF-A 
distribution and availability is critical for normal blood vessel development and 
patterning (Ruhrberg et al., 2002; Stalmans et al., 2002) (Gerhardt et al., 2003)}. 
 The downstream components of the VEGF signaling pathway have also been 
studied extensively (Olsson et al., 2006).  VEGF stimulation of endothelial cells 
results in the phosphorylation of many signaling proteins including phospholipase C 
(PLCγ), which leads to the activation of mitogen activated protein kinase 
(MAPK)/ERK1/2 cascade and proliferation of endothelial cells (Takahashi and 
Shibuya, 2001).   Other targets include phosphatidylinositol 3’ kinase (PI3K), which 
is involved in survival (Gerber et al., 1998); c-Src, which is involved in vascular 
permeability and migration (Chou et al., 2002; He et al., 1999); and focal adhesion 
kinase (FAK), which also plays a role in migration (Abedi and Zachary, 1997).  
These upstream signaling components, along with others, are stimulated via VEGF-
A, and eventually lead to changes in gene expression, as well as modulation of other 
pathways that regulate cell division, morphogenesis, and survival.  Much of my own 
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thesis work revolves around the question of how modulating VEGF-A stimulation of 
Flk-1, via Flt-1, can affect cell proliferation and migration during vascular 
morphogenesis.   
 
2.  Flk-1 (VEGFR-2) 
 The Flk-1 receptor belongs to a subfamily of receptor tyrosine kinases (RTKs) 
implicated in both vasculogenesis and angiogenesis.  Flk-1 is first expressed in 
embryonic lateral mesoderm at E6.5, and subsequently observed at low levels in 
many mesoderm progenitors (E6.5-8.5) as well as later mesodermal cell types 
including cardiomyocytes and somite (E8.5) (Ema and Rossant, 2003) (Ema et al., 
2006). Flk-1 is also expressed in angioblasts surrounding the blood islands around 
E7.0 (Shalaby et al., 1995).  Flk-1 is subsequently expressed on mature endothelial 
cells and binds VEGF-A with high affinity (Quinn et al., 1993; Terman et al., 1992).  
Genetic deletion of Flk-1 results in embryos that die in utero between E8.5 and E9.5 
from early defects in hematopoietic and endothelial cell development (Shalaby et al., 
1995).  Furthermore, targeted deletion of Flk-1 in ES cell cultures resulted in a 
drastic reduction of vascular endothelium formation, mimicking the phenotype 
observed in vivo (Shalaby et al., 1997).  Moreover, the addition of either a 
neutralizing antibody against VEGF-A, or a dominant negative form of Flk-1 was 
able to block angiogenesis (Kim et al., 1993; Millauer et al., 1994).  In vitro cell 
culture experiments have also demonstrated a requirement for Flk-1 on VEGF-A-
dependent cell division, migration, and survival (Bernatchez et al., 1999; Gerber et 
al., 1998; Waltenberger et al., 1994).  Thus, Flk-1 is required for proper 
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hematopoietic and vascular endothelial cell formation, as well as VEGF-A-
dependent endothelial cell function. 
 Flk-1 is an RTK that has seven immunoglobulin-like repeats in the 
extracellular domain (VEGF-binding domain), a single transmembrane region, a 
juxta-membrane domain, followed by a cytoplasmic tail with docking sites and a 
tyrosine kinase domain (Fuh et al., 1998).  VEGF-A binding to Flk-1 results in 
dimerization and activation of the receptor (review) (Schlessinger, 2000).  This 
results in autophosphorylation of Flk-1, leading to the activation of many 
downstream targets, which is consistent with the idea that Flk-1 mediates many 
biological effects in response to VEGF-A (review) (Olsson et al., 2006). 
VEGF-dependent Flk-1 activation has been shown to activate several signaling 
pathways in endothelial cells.  Briefly, VEGF-A stimulates phospholipase Cγ (PLCγ), 
which can in turn activate Protein Kinase C (PKC)  to induce cell proliferation via the 
Raf-MEK-MAP-kinase cascade (Guo et al., 1995; Wellner et al., 1999; Xia et al., 
1996).  VEGF/Flk-1 activation of phosphoinositide 3-kinase (PI3K) stimulates Akt, a 
protein involved in endothelial cell survival (Gerber et al., 1998; Gliki et al., 2002).  
Flk-1 activation and downstream signaling is also important for endothelial cell 
migration.  It is believed that actin reorganization and focal adhesion turnover both 
contribute to endothelial cell migration. Actin reorganization is potentially mediated 
by p38 MAPK and Rac (Bernatchez et al., 2001), while focal adhesion turnover is 
stimulated through focal adhesion kinase (FAK) (Abedi and Zachary, 1997) and c-
Src, which regulate the interactions between the extracellular matrix and the actin-
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cytoskeleton, thus playing a role in endothelial cell movement (Abedi and Zachary, 
1997; Abu-Ghazaleh et al., 2001; Bernatchez et al., 2001; Rousseau et al., 2000).   
These studies indicate that VEGF-A exerts most of its growth promoting 
effects on the vasculature through its association and activation of the Flk-1 
receptor.  Moreover, although many studies have shown that VEGF-A signaling 
through Flk-1 promotes the positive effects of vessel morphogenesis (review) 
(Carmeliet, 2000), chapters II and III of this dissertation will focus on the role of Flt-1 
as a positive regulator of blood vessel morphogenesis. 
  
3.  Flt-1 (VEGFR-1) 
 Flt-1 (VEGFR-1), a second high affinity VEGF receptor that is also a receptor 
tyrosine kinase, is important in blood vessel formation and development. 
Flt-1 expression is first detected in angioblasts around E6.5-E7.0 of mouse 
development (Peters et al., 1993).  Its expression decreases slightly during late 
gestation, but is expressed at high levels in most adult vessels.  Flt-1 is also 
expressed on monocytes/macrophages (Barleon et al., 1996; Clauss et al., 1996), 
smooth muscle cells (Wang and Keiser, 1998), and trophoblasts (Ahmed et al., 
1995).  Genetic studies in mice have shown that deletion of flt-1 results in embryonic 
lethality at mid-gestation (E9.5).  The phenotype associated with this lethality, 
however, is very different from a genetic deletion of Flk-1: a highly disorganized 
vascular endothelium.  Flt-1-/- mice also have excess endothelial cells in the yolk 
sac and heart endocardium (Fong et al., 1995).  Studies using mouse ES cell-
derived vessels show that the increase in endothelial cell numbers is a result of 
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increased endothelial cell proliferation (Kearney et al., 2002; Kearney et al., 2004).  
Thus, the excess numbers of endothelial cells in Flt-1 mutants suggests that Flt-1 
negatively regulates vessel development by limiting the number of endothelial cells 
produced.   
 Flt-1 is expressed as a full-length receptor tyrosine kinase (mFlt-1) and as a 
soluble isoform (sFlt-1) that consists of only the first six N-terminal IgG-like 
extracellular ligand-binding domains (Kendall and Thomas, 1993; Kendall et al., 
1996).  Soluble Flt-1 is generated by alternative splicing of Flt-1 RNA (Kendall and 
Thomas, 1993).  Full-length Flt-1 is organized into four different domains.  The Flt-1 
receptor contains an extracellular domain (7 IgG-like domains), a single 
transmembrane region, a juxta-membrane domain, followed by a cytoplasmic tail 
with docking sites and a tyrosine kinase domain (Olsson et al., 2006).  The 
extracellular domain binds VEGF-A with a 10-fold stronger affinity for VEGF-A than 
that of Flk-1 (Kondo et al., 1998; Park et al., 1994).   
 
The molecular mechanisms that underlie Flt-1 function are not completely 
understood.  VEGF binding through the Flt-1 receptor produces a relatively weak 
tyrosine autophosphorylation in cultured endothelial cells (Seetharam et al., 1995) 
that does not transduce a mitogenic signal (de Vries et al., 1992; Shibuya et al., 
1990; Waltenberger et al., 1994).  The Flt-1 intracellular domain contains binding 
sites for PLC-γ, PI-3’kinase, and Src, suggesting a signaling role for Flt-1 in cell 
survival and migration (Cunningham et al., 1995; Ito et al., 1998; Waltenberger et al., 
1994).  In vitro studies have shown interactions between the Flt-1 intracellular 
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domain and Crk, a protein involved in focal adhesion signaling and cell motility (Ito et 
al., 1998).  However, mice lacking the cytoplasmic domain of the Flt-1 receptor are 
viable and undergo normal vascular development, indicating that the signaling 
function of the Flt-1 receptor is not essential during embryonic development 
(Hiratsuka et al., 1998).  The fact that vessels create a soluble form of Flt-1, in 
conjunction with the data revealing that the cytplasmic domain is dispensible for 
proper vascular development, has led to a model in which Flt-1 may act as a decoy 
molecule to bind and sequester VEGF-A during development.  Flt-1-/- ES cell-
derived vessels have approximately 3-fold higher levels of activated Flk-1 than do 
normal vessels, consistent with a role for Flt-1 in ligand sequestration (Roberts et al., 
2004). A recent study identified a single amino acid in the kinase domain of Flt-1 that 
severely reduces kinase activity and signaling, further suggesting its role as a ligand 
sink (Meyer et al., 2006).  Moreover, a study using Flk-1 and Flt-1 chimeric receptors 
showed that the intracellular juxtamembrane region in Flt-1 suppresses VEGF-A-
dependent activation of PI 3’-kinase and subsequent endothelial cell migration (Gille 
et al., 2000), further suggesting a non-signaling role for Flt-1 during development.   
Collectively, this data suggests that Flt-1 functions in vascular development as a 
ligand sink to bind and sequester VEGF-A, and thus regulate signaling through the 
Flk-1 receptor. 
Although Flt-1 signaling during development is not essential for proper 
vascular development, Flt-1 does appear to function as a positive regulator of 
ischemic and pathological revascularization (Luttun et al., 2002).  Placental Growth 
Factor (PlGF) and VEGF-B, two Flt-1-specific ligands, are required for these 
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functions (Bellomo et al., 2000; Olofsson et al., 1998; Park et al., 1994).  PLGF also 
promotes recruitment of hematopoietic stem cells via Flt-1, from a quiescent to a 
proliferative microenvironment within the bone marrow, favoring differentiation, 
mobilization, and reconstitution of hematopoiesis (Rafii et al., 2003).  Collectively, 
this data further implicates Flt-1 signaling function primarily in the adult. 
 Chapter II of this dissertation describes evidence that Flt-1 is a negative 
regulator of cell division in ES cell-derived vessels, and a positive regulator of vessel 
branching in ES cell-derived vessels and in vivo.  However, there are unanswered 
questions regarding the role of flt-1 during vascular development.  Data from chapter 
II shows evidence to suggest that the secreted form of Flt-1 is important in regulating 
vessel branching.  Here we propose a model in which sFlt-1 may modulate an 
existing VEGF-A gradient to regulate vessel branching. Although it remains unclear 
to what extent the mFlt-1 isoform regulates vascular development, it has been 
suggested that membrane-tethered Flt-1 is required developmentally for the proper 
delivery of VEGF-A to the endothelial cell membrane (Hiratsuka et al., 2005).  This 
idea is supported by the observation that mice that do not express membrane-
tethered Flt-1 succumb to embryonic lethality half of the time due to poor blood 
vessel development on the C57BL6/J genetic background.  The lack of mFlt-1 in 
these mice results in reduced membrane-targeted VEGF-A to endothelial cells, and 
the subsequent suppression of Flk-1 phosphorylation on endothelial cells (Hiratsuka 
et al., 2005).  Their conclusion, however, is ambiguous, as there is an observed 99% 
survival rate in mice lacking mFlt-1 on the 129 genetic background (Hiratsuka et al., 
2005).  The authors point to increased Flk-1 expression in 129 mice as the reason 
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for this high survival rate, however, their explanation is not well supported.  Thus, 
there is no conclusive evidence to explain the role of mFlt-1 during development.  In 
chapter III, I have attempted to get a clearer understanding of the role of mFlt-1 and 
sFlt-1 in vascular development, specifically vessel branching and proliferation, by 
reintroducing isoform-specific Flt-1 transgenes into flt-1-/- ES cell-derived vessels.
  
 
CHAPTER II 
THE VEGF RECEPTOR FLT-1 (VEGFR-1) IS A POSITIVE MODULATOR OF 
VASCULAR SPROUT FORMATION AND BRANCHING MORPHOGENESIS 
 
A.  Introduction 
 The first step in the formation of most blood vessels is the production of an 
intricately branched vascular plexus (reviews) (Daniel and Abrahamson, 2000; 
Drake et al., 1998; Risau, 1997).  This plexus is subsequently pruned and 
remodeled, and in some cases coalesced to form larger vessels.  The primary 
branched plexus forms by several processes, including the initial assembly of 
vascular precursor cells called vasculogenesis, and the subsequent migration of 
endothelial cells from the parent vessel called sprouting angiogenesis.  The sprouts 
that form migrate until they reach another sprout or vessel, whereupon they most 
often form connections that are essential for elaborating and expanding the 
branched network.  Although the formation of vascular sprouts has been described 
historically (Clark and Clark, 1939; Sabin, 1920), surprisingly little is known of the 
cellular processes and molecular controls of sprout formation, and even less is 
known about how these processes are integrated with other ongoing cellular events 
such as cell division. 
The vascular sprouts that form during embryonic development extend from 
primitive vessels.  Individual endothelial cells send out filopodia, then migrate away 
from the parent vessel without breaking all contacts with surrounding cells, so that 
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eventually multiple cells comprise the sprout.  Cell numbers in the sprout are also 
increased by cell division behind the leading tip of the sprout (Ausprunk and 
Folkman, 1977; Clark and Clark, 1939).  Formation of a branched vascular plexus 
depends on the regulated expression of vascular endothelial growth factor-A (VEGF-
A) by non-endothelial cells.  This signal modulates intracellular signaling pathways 
that regulate endothelial cell division, migration, and survival (review) (Matsumoto 
and Claesson-Welsh, 2001a).  This regulation is dose-dependent, as modest 
changes in the amount of available VEGF-A in either direction compromise vascular 
development, and loss of even one copy of the Vegf-A gene leads to vascular 
disruption and embryonic lethality (Bautch et al., 2000; Carmeliet et al., 1996; 
Damert, 2002; Ferrara et al., 1996; Miquerol et al., 2000).  Availability also seems to 
be regulated by the production of different isoforms of VEGF-A via alternative 
splicing.  These isoforms have differing affinities for matrix components, and 
disruption of individual isoforms affects vessel morphogenesis (Park et al., 1993; 
Ruhrberg et al., 2002; Stalmans et al., 2002).  
VEGF-A signals through two receptor tyrosine kinases, flk-1 (VEGFR2) and 
flt-1 (VEGFR1).  VEGF/flk-1 interactions positively influence endothelial chemotaxis 
and proliferation, but the outcomes of VEGF/flt-1 interactions are less clear-cut 
(Bernatchez et al., 1999; Waltenberger et al., 1994).  The flt-1 gene encodes both a 
receptor tyrosine kinase (mflt-1) and a secreted splice variant, sflt-1, that consists of 
the flt-1 extracellular domain.  sflt-1 binds VEGF-A with high affinity and is a potent 
antagonist of VEGF/flk-1 signaling (Kendall and Thomas, 1993; Kendall et al., 1996).  
Mouse mutants lacking flt-1 die at embryonic day 9.5 with highly disorganized blood 
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vessels and excess endothelial cells (Fong et al., 1995), yet a mouse with a modified 
flt-1 gene that lacks most of the cytoplasmic domain is viable (Hiratsuka et al., 
1998), suggesting that sflt-1 is sufficient for the developmental role of flt-1.  We 
recently showed that flt-1 negatively modulates endothelial cell division (Kearney et 
al., 2002), but the role of flt-1 in endothelial cell migration remains unclear.  In vitro 
studies, including analysis of chimeric VEGF receptors, failed to demonstrate a role 
for flt-1 in endothelial migration (Bernatchez et al., 1999; Gille et al., 2001; Rahimi et 
al., 2000; Waltenberger et al., 1994; Zeng et al., 2001).  However, a study in which 
VEGF/flt-1 binding was selectively blocked suggested that flt-1 promotes VEGF-
dependent actin reorganization and migration (Kanno et al., 2000). 
      In the course of investigating the effects of a flt-1 null mutation on blood 
vessel formation, we noticed aberrant morphogenesis of flt-1-/- embryonic vessels 
(Kearney et al., 2002).  Thus we reasoned that flt-1 might modulate the VEGF-
induced endothelial cell migration that occurs during embryonic sprouting 
angiogenesis.  Our use of confocal time-lapse imaging afforded us the unique ability 
to analyze dynamic processes of mammalian vascular development.  Vascular 
sprout formation was analyzed in wild-type and flt-1-/- mutant ES cells induced to 
differentiate to form primitive vessels.  To our surprise, flt-1-/- blood vessels exhibited 
decreased sprout formation, and the flt-1-/- mutant sprouts that formed had a 
reduced migration rate.  Moreover, flt-1-/- embryos showed defective sprouting of 
vessels from the dorsal aorta.  This defect is likely not an immediate consequence of 
increased endothelial cell division in the mutant background, since the sprouting 
defect persisted after endothelial cell division rates returned to normal in flt-1-/- 
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mutant vessels.  Rather, rescue of the mutant phenotype with an sflt-1 transgene 
suggests a model whereby sflt-1 protein interacts locally with VEGF-A.  This 
interaction is predicted to establish or modify a gradient that regulates vascular 
sprouting and endothelial cell migration. 
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B.  Materials and Methods 
 
Cell culture and in vitro differentiation   
Wild type (WT, +/+) and flt-1-/- ES cells (Fong et al., 1995) containing an 
eGFP or an sflt-1 transgene under the transcriptional control of the PECAM 
promoter/intron 2 enhancer element (Robson, P., Ellerstrom, C., Bautch, V.L., and 
Baldwin, H.S., in preparation) were maintained and differentiated in vitro as 
described previously (Bautch et al., 1996).  Cultures were plated onto slide flasks 
(Nalge Nunc, Rochester NY) at day 3 of differentiation and cultured at 37oC in 5% 
CO2 until time-lapse imaging was performed.   
 
DNA constructs and electroporation 
The PECAM promoter/enhancer (gift of H.S. Baldwin, Robson et al., in prep) 
was cloned into a modified eGFP vector (BD Clontech, Palo Alto CA) for 
electroporation into WT ES cells, and designated PECAM-eGFP.  PGK-HygroR (gift 
of N. Maeda) was then inserted into the PECAM-eGFP vector for electroporation into 
flt-1-/- ES cells, and designated PECAM-eGFP-HygroR .  sflt-1 cDNA was generated 
by RT-PCR amplification of a 500 bp fragment of sflt-1 (nt 1834-2544) from WT day 
8 ES cell cultures, which was cloned via the TA method (Promega) and verified by 
sequence analysis.  A 2.1 kb XbaI fragment from mflt9 (mouse flt-1 cDNA, gift of G. 
Breier (Breier et al., 1995)) that encompassed nt 1-2134 of full-length flt-1 was 
cloned into the unique XbaI site at position 2134 of the sflt-1 clone.   The sflt-1 cDNA 
was cloned into the PECAM-HygroR vector and designated PECAM-sflt-1.   
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20µg of linearized PECAM-eGFP and PECAM-eGFP-HygroR DNAs were 
electroporated into 2 x 107 ES cells using a BioRad GenePulser II electroporator 
(250V/300µF).  WT ES cell selection was in 200 µg/ml G418 (Gibco, Carlsbad CA), 
and selection of flt-1-/- ES cells was in 200 µg/ml hygromycin B (Roche Diagnostics, 
Indianapolis IN).  After 10-12 days, drug resistant ES colonies were picked, 
expanded, and analyzed.  We initially analyzed 3 WT transgenic lines (designated 
as WT; Tg pecam-egfp) and 4 flt-1-/- transgenic lines (designated as flt-1-/-; Tg 
pecam-egfp), and saw no differences except by genotype, so single WT and mutant 
lines were used.  PECAM-eGFP and PECAM-sflt-1 were linearized and 
electroporated into flt-1-/- ES cells at a 1:3 molar ratio as described above.  After 
selection in hygromycin B, drug resistant ES colonies that expressed eGFP were 
picked and analyzed. 
 
Time-lapse imaging and quantitative analysis 
Slide flasks containing day 6-8 in vitro differentiated ES cultures were sealed, 
then placed on a heated stage on a Nikon TE300 inverted microscope with a Perkin 
Elmer spinning disk confocal head.  Confocal images were acquired at 1 min 
intervals using Metamorph software (version 6.0, Universal Imaging Corp., 
Downingtown PA) and a Hamamatsu Orca CCD camera with a 20x objective.  
Quantitative image analysis was performed using Metamorph software.  For sprout 
index measurements, total vessel perimeter was determined by outlining vessels 
and measuring total line length.  Sprouts were defined as endothelial cell projections 
that included cytoplasm and were at least 10 µm in length.  For sprout velocity 
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measurements, total sprout length was determined by measuring the distance from 
the tip of the sprout to the point at which the sprout joined the primary vessel wall.  
For cell division score measurements, average percentage of GFP-positive area was 
determined for each movie by threshholding and averaging 3 separate frames: the 
first, middle, and last frame.  Significance was determined using the two-tailed 
student’s T test. 
For fixed branch point analysis, cultures labeled with anti-PECAM antibody 
were photographed using a Nikon eclipse E800 upright microscope at 10x 
magnification.  Vessel length was determined by tracing a vascular skeleton, and 
measuring total line length using Metamorph software.  Branch points were identified 
by visual scoring of each frame.   
 
Antibody and β-galactosidase staining   
Following time-lapse imaging, ES cell cultures were rinsed with phosphate 
buffered saline (PBS) and fixed for 5 minutes in ice-cold methanol:acetone (50:50).  
Fixed cultures were reacted with rat anti-mouse PECAM at 1:1000 (MEC 13.3; B-D 
Pharmingen, San Diego CA) and donkey anti-rat immunoglobulin G (IgG; H+L) 
TRITC cross-absorbed at 1:100 (Jackson Immunoresearch, West Grove PA) 
antibodies as described previously (Bautch et al., 2000; Bautch et al., 1996).  All 
cultures were viewed and photographed with an Olympus IX-50 inverted microscope 
outfitted with epifluorescence.  PECAM images were aligned with the last frame of 
each movie using Photoshop version 5.5 (Adobe Systems, San Jose CA).  Co-
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cultures were fixed and processed for β-galactosidase reactivity as described 
(Kearney et al., 2002). 
 
Embryo manipulations 
 
 Flt-1+/- mice were intercrossed, and embryos were dissected at 8.5 dpc (days 
post-coitum), and fixed overnight in 4% PFA at 4oC.  Yolk sacs were used for 
genotyping as described (Kearney et al., 2002).  The next day embryos were 
dehydrated through a MeOH series, then rehydrated and whole mount stained for 
PECAM-1 as described (Redick and Bautch, 1999).  After staining, embryos were 
visualized and photographed on an Olympus SZH10 dissecting microscope. 
 
 
 
C.  Results 
 
Dynamic image analysis of vascular sprout formation 
 
 To assay dynamic components of vascular morphogenesis, we generated 
stable ES cell subclones using a PECAM promoter/enhancer reporter in WT and flt-
1-/- genetic backgrounds (see Methods for details).  A subset of drug resistant 
subclones expressed eGFP in the endothelial lineage upon differentiation.  Based on 
phenotypic similarities, we chose a single WT line (P27, WT-eGFP) and a single flt-
1-/- line (GG5-15, flt-1-/--eGFP) for further analysis.  To confirm that expression of the 
reporter recapitulated expression of endogenous PECAM, we fixed day 8 WT-eGFP 
and flt-1-/--eGFP ES cell differentiation cultures after time-lapse image analysis and 
stained for PECAM (Fig. 1).  These images were overlayed with the last GFP image 
filmed (Fig. 1Ac, f, i).  The congruence of the images showed that the eGFP 
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reporters were expressed in the same cells that also expressed endogenous 
PECAM, and in all cases expression was associated with blood vessels.  While the 
majority of PECAM+ cells were endothelial cells lining the vessels, a small number 
of cells within the vessels also expressed PECAM, and these are likely to be the 
subset of hematopoietic cells that are PECAM+.  The apparent lack of eGFP 
expression in a subset of PECAM-positive cells results from the comparison of 
confocal (Fig. 1Aa, d, g) with epifluorescence (Fig. 1Ab, e, h) images, since confocal 
images had a thinner focal plane.  These data also confirm that the vascular 
phenotypes of the eGFP-expressing ES cell subclones recapitulate the parental 
vascular phenotypes (Fong et al., 1999; Kearney et al., 2002).  Specifically, a 
branched vascular plexus was seen in WT-eGFP cultures (Fig. 1Aa-c), while both 
sheets of endothelial cells (Fig. 1Ag-i) and some branched areas (Fig. 1Ad-f) were 
seen in the flt-1-/--eGFP cultures.  Finally, these results confirm that the conditions of 
time-lapse imaging do not adversely affect vascular development in the ES cell 
cultures.   
We next asked whether a specific morphogenetic behavior, the formation of a 
vascular sprout, was recapitulated in ES cell differentiation cultures (Fig. 1B and 
Movie 1).  Day 8 WT-eGFP ES differentiation cultures were imaged for 2-10 hours.  
The resulting images were examined for sprout formation, as defined by projections 
from the parent structure that were at least 10 µm in length and were GFP positive.  
Numerous examples of sprout formation were noted, and one example is shown in 
Fig. 1B.  This sprout initiated, extended, and formed a connection with a sprout from 
another area within a 145 minute period.  The eGFP reporter did not allow for 
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precise location of cell boundaries, but the sprout length was approximately 20 µm at 
maximum, suggesting that it was comprised of one or at most two endothelial cells.  
Most sprouts that formed in WT cultures either joined with another sprout or part of a 
vessel, or they remained in place as sprouts at the end of filming (Fig. 2A and data 
not shown).  Rarely, sprouts formed and retracted during the period of filming.  
These results show that ES cell differentiation is an appropriate model system for 
visualization and analysis of vascular morphogenetic processes in the mammal. 
 
Sprout formation and function is compromised in the absence of flt-1 
 To determine how flt-1 affects vascular morphogenesis at the cellular level, 
we next compared sprout formation between WT and flt-1-/- vessels using dynamic 
image analysis (Fig. 2A-B and Movies 2-3).  Because flt-1-/- ES cell cultures had 
areas of endothelial sheets, we were careful to score mutant sprout formation only in 
areas of flt-1-/- ES cell cultures that contained a vascular plexus (i.e. Fig. 1Ad-f, Fig. 
2Ad-f).  To measure sprout formation, a sprout index that was normalized for time 
and vessel perimeter was calculated for multiple movies of each genotype.  Since 
the lack of flt-1 leads to increased rates of endothelial cell division via upregulation of 
VEGF signaling (Kearney et al., 2002; Roberts et al., 2004), we hypothesized that 
morphogenetic parameters such as sprout formation would also be increased in the 
flt-1-/- genetic background.  To our surprise, flt-1-/- vessels had a reduced sprout 
index relative to WT vessels.  The sprout indices for d6 and d8 WT-eGFP time-lapse 
movies (Fig. 2B, grey circles) had a wider distribution that ranged much higher than 
day-matched flt-1-/--eGFP movies (Fig. 2B, black circles).  Furthermore, flt-1-/--eGFP 
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vessels showed a 2.5 fold decrease in average sprout formation index over day-
matched WT controls.  These results show that flt-1-/- blood vessels sprout less often 
than WT blood vessels.  
We next determined whether the absence of flt-1 affects the rate of sprout 
migration.  Analysis of time-lapse images was used to determine average sprout 
velocity (sprout vessel tip displacement/time) for flt-1-/--eGFP vascular sprouts and 
WT control sprouts (Fig. 2C-D and Movies 4-5).  Sprout vessel tips (Fig. 2C, white 
arrowheads) were tracked over time using the base of the sprout at each time as the 
reference point.  A plot of the average velocity for individual sprouts (Fig. 2D) 
showed that flt-1-/--eGFP sprouts (black circles) displayed a lower range of velocities 
than WT-eGFP sprouts.  Moreover, flt-1-/--eGFP sprouts had a mean average sprout 
velocity that was reduced by 36% compared to WT-eGFP sprouts.  This result 
indicates that flt-1 also modulates the speed with which sprouts migrate along a 
vector once they form. 
We confirmed these results with a more traditional assay that is reflective of 
sprout formation, branch point analysis.  Fixed samples of day 8 WT-eGFP and flt-1-
/--eGFP differentiated ES cell cultures were labeled with PECAM to visualize vessels 
(Fig. 3).  flt-1-/--eGFP and WT-eGFP vascular plexi showed a range of branch point 
densities (Fig. 3A), but flt-1-/--eGFP ES cell cultures had less complex networks of 
blood vessels on average than WT controls (compare Fig. 3Aa-c with d-f).  
Quantitation showed that flt-1-/--eGFP ES cell cultures had a 30-40% decrease in 
branch point formation relative to WT (Fig. 3B).  Thus, the fixed branch point data 
are consistent with the time-lapse data, and they support a model whereby flt-1 
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normally modulates vessel morphogenesis by positively regulating both the 
frequency of endothelial sprout formation and the rate of sprout migration. 
To determine if the reduced sprout formation seen in the absence of flt-1 was 
also seen in vivo, we examined the formation of intersomitic vessels that arise via 
sprouting angiogenesis from the dorsal aorta (Fig. 4A).  At 8.5 dpc, wild-type 
embryos consistently had several intersomitic vessels, and well-defined vascular 
sprouts were seen in register posterior to the vessels (Fig. 4Aa-c).  In contrast, day-
matched flt-1-/- embryos had very few intersomitic sprouts, and those that formed 
were short and seldom connected to the vertebral vessel (Fig. 4Ad-f).  Thus the 
sprout defect documented in vascular development in ES differentiation cultures is 
also seen in mutant embryos lacking flt-1.  
 
 We reasoned that if sprout formation and migration were affected in the 
absence of flt-1, the endothelial cells at the tip of the sprout might have an abnormal 
morphology.  Indeed, our examination of sprouts in flt-1-/- embryos suggested that 
sprout tips tend to be blunted in the absence of flt-1 (Fig. 4A, inset e, and f).  To 
analyze this observation more carefully, we examined the morphologies of WT and 
flt-1-/- mutant sprouts in ES cell differentiation cultures (Fig. 4B).  WT sprout tips in 
general gradually tapered to a point, although rare WT sprouts were less tapered 
(Fig. 4Ba-d).  In contrast, more of the flt-1-/- mutant sprout tips were blunted (Fig. 
4Be-h), consistent with our findings that sprout migration along a vector is reduced.         
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Cell division defects are not immediately upstream of morphogenesis defects 
in flt-1-/- mutant vessels 
 We previously showed that flt-1-/- ES cultures display a 2-3 fold increase in 
endothelial cell division on day 6 of differentiation (Kearney et al., 2002).  To 
determine if this difference was also observed with dynamic image analysis, we 
scored endothelial cell mitoses in flt-1-/--eGFP ES cell differentiation cultures and in 
WT controls (Fig. 5 and Movies 6-7).  Day 6 flt-1-/--eGFP cultures had increased 
numbers of mitotic endothelial cells compared to WT controls (compare Fig. 5A and 
5B).  The number of endothelial cell divisions per hour was normalized for vascular 
area and used to produce a mitotic score that was averaged for multiple movies of 
both genotypes (Fig. 5C).  Day 6 flt-1-/--eGFP vessels had an average mitotic score 
that was increased over WT-eGFP vessels by greater than 2-fold, consistent with 
our previous results (Kearney et al., 2002).  However, the differences in mitotic score 
between WT and flt-1-/- mutant vessels were resolved by day 8, a time point that was 
not assayed in our original study. 
One explanation for the decreased frequency of sprout formation in the 
absence of flt-1 is the possibility that the increased rate of cell division precludes 
sprout formation and migration.  The fact that day 8 flt-1-/--eGFP cultures had the 
same mitotic score as day-matched WT controls, whereas the sprout index and 
sprout velocity were still significantly decreased at day 8 in the flt-1-/- mutant vessels, 
suggests that this simple explanation is not valid.  Time-lapse analysis provided the 
opportunity to observe the temporal and spatial positioning of endothelial cell 
divisions relative to sprout formation and maturation (Table 1).  The sprout field was 
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defined as the area of the primary vessel wall that would in the near future give rise 
to a sprout, and the sprout itself.  The rest of the structure was classified as primary 
vessel.  Significant cell divisions occurred in the sprout field, and we even saw rare 
divisions in the distal-most tip cell of the sprout in both wild-type and flt-1-/- mutant 
vessels (data not shown), indicating that cell division and sprout formation/migration 
are not mutually exclusive over time.  Moreover, the distribution of mitoses between 
the primary vessel and the sprout field was similar between WT and flt-1-/- mutant 
vessels on both days, indicating that the flt-1 mutation does not change the 
distribution of endothelial mitoses. 
 
Aberrant flt-1-/- vascular morphogenesis is rescued in a non cell-autonomous 
manner and with an sflt-1 transgene 
 To begin to determine the mechanism whereby flt-1 positively affects vascular 
morphogenesis, we asked whether sflt-1, the soluble antagonist of VEGF signaling, 
was generated coincident with vascular morphogenesis during ES cell 
differentiation.  Day 8 wild-type and flt-1+/- heterozygous ES differentiation cultures 
expressed sflt-1 RNA and protein, and as predicted both RNA and protein were 
undetectable in day-matched flt-1-/- ES differentiation cultures (data not shown).  We 
reasoned that if flt-1 positively regulates sprout formation via effects of the sflt-1 
protein, it might be possible to rescue the morphogenetic defect in flt-1-/- vessels in a 
non cell-autonomous manner.  To test this hypothesis, we co-cultured wild-type and 
flt-1-/- mutant embryoid bodies (EBs) in the same wells, by allowing EBs of both 
genotypes to attach on day 3 and continue differentiation to day 8 (Fig. 6A).  In 
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contrast to flt-1-/- vessels that consisted of large sheets with a few sprouts at the 
edges, flt-1-/- vessels in wells with wild-type EBs (ratio 3 WT: 1 mutant) showed 
areas of significant rescue and increased branching (compare Fig. 6Aa to 6Ab).  
Thus the morphogenetic defect of flt-1-/- vessels can be rescued in a non cell-
autonomous manner, suggesting that sflt-1 and/or some other soluble component is 
critical to normal vascular morphogenesis. 
To directly address the role of sflt-1 in vascular morphogenesis, we 
reintroduced sflt-1 into flt-1-/- ES cells.  A PECAM-sflt-1 transgene was expressed in 
day 8 flt-1-/-PECAM-sflt cultures by RT-PCR (data not shown), and this was 
accompanied by a rescue of the mutant vascular phenotype (Fig. 6B).  A branch 
point analysis was performed, and the flt-1-/-PECAM-sflt cultures had rescued 
branching, with values that fell between WT and mutant cultures and that were 
significantly increased from flt-1-/- cultures (Fig. 6C).   
 
 
 
 
 
 35
D.  Discussion 
 
 Our results show that flt-1 modulates vascular sprout formation 
developmentally.  To our surprise, this modulation is positive, and flt-1 is required for 
proper sprout formation and migration.  The data that support this conclusion are: 1) 
the rate of sprout formation and migration are both decreased in the absence of flt-1, 
2) decreased vascular branching accompanies loss of flt-1 during ES cell 
differentiation and is rescued by an sflt-1 transgene, and 3) decreased sprouting 
from the dorsal aorta results from loss of flt-1 in vivo.  Our data support a model 
whereby flt-1 affects vascular morphogenesis via a soluble mediator that is likely to 
be sflt-1, suggesting that formation and/or modulation of a VEGF gradient may be 
important to the effect of flt-1 on vascular sprout formation (Fig. 7). 
 
How does flt-1 affect morphogenesis? 
 Since flt-1-/- endothelial cells have a higher rate of division than do wild-type 
endothelial cells (Kearney et al., 2002), it was possible that the cell division defect 
was immediately upstream of the morphogenetic defect.  That is to say, the 
endothelial cells possibly were too busy dividing to migrate.  There is precedent for 
this model, in that both normal and tumor vessels restrict cell divisions to sprout 
areas more proximal to the parent vessel (Ausprunk and Folkman, 1977; Clark and 
Clark, 1939; Gerhardt et al., 2003), suggesting that actively migrating and sensing 
cells are prevented from dividing.  Moreover, in tubulogenesis in the fly trachea, the 
tracheal precursor cell pool divides to produce all the tracheal cells, which then 
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migrate and form the tracheal tubes in the absence of further cell division (Metzger 
and Krasnow, 1999).  
 
Our use of time-lapse image analysis allowed us to determine the relationship 
between cell division and cell migration with finer resolution than with end point 
analyses, and it showed that endothelial cells in a migratory mode can also undergo 
cell division.  The cells did not migrate during mitosis or for some time prior to 
mitosis, but once division was complete the daughter cells often migrated quite 
rapidly to resume sprout formation.  We found that divisions were not excluded from 
the “sprout field” but in fact were in most cases enriched in the sprouts and their 
vicinity (N.C.K. and V.L.B., unpub. results), suggesting that sprout formation may 
stimulate cell division.  We even on occasion saw the most distal cell of the sprout 
undergo mitosis in both WT and flt-1-/- mutant vessels, although this event did not 
occur with high frequency.  This finding differs from a recent study that found no tip 
cell division in retinal vessels (Gerhardt et al., 2003).  However, retinal vessels track 
along a VEGF template provided by astrocytes, while in our model and in many 
developmental vascular beds the source of VEGF is likely to be more diffuse.  Thus 
sprouts may have distinct phenotypes in response to different presentations of 
agonist.  Finally, we saw no difference in the distribution of cell divisions to different 
areas of the vessel in the flt-1-/- vessels compared to controls, indicating that flt-1 
does not regulate this parameter of cell division.  It is formally possible that aberrant 
cell division in flt-1-/- mutant vessels somehow compromises sprout formation, since 
there are more endothelial cell divisions in the flt-1 mutant background.  However, 
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the observation that the sprouting defects persist at day 8, when the rate of cell 
division in mutant vessels has returned to wild-type levels, strongly suggests that the 
effect of flt-1 on sprout formation and extension is independent of cell division. 
Flt-1 is a negative regulator of VEGF-A/flk-1 signaling (Kendall and Thomas, 
1993; Roberts et al., 2004), and VEGF-A and flk-1 are both expressed during ES cell 
differentiation and required for vessel formation (Bautch et al., 2000; Shalaby et al., 
1997).  Thus the flt-1-/- mutant vessels were expected to have increased sprout 
formation and migration.  Instead, flt-1-/- mutant sprouts formed less frequently and 
had slower migration rates.  There are several models that are consistent with this 
phenotype.  Perhaps VEGF signaling through the flt-1 receptor (mflt-1) positively 
modulates endothelial cell migration developmentally, and the absence of this 
receptor in flt-1 mutants blocks this positive migratory pathway.  VEGF/flt-1 signaling 
induces actin reorganization in cultured endothelial cells (Kanno et al., 2000), and 
the flt-1 kinase domain interacts with proteins involved in cell migration (Ito et al., 
1998).  However, a mouse model that lacks the flt-1 kinase domain shows normal 
vascular development, and stimulation of retinal vessels with PlGF, which binds flt-1 
but not flk-1, did not affect filopodia formation (Gerhardt et al., 2003; Hiratsuka et al., 
1998).  These findings suggest that signaling through the flt-1 receptor is not 
required for proper sprout formation developmentally.  
Another possible model to explain reduced sprouting in the absence of flt-1 is 
that mflt-1 and/or sflt-1 negatively modulate local interactions between VEGF-A and 
flk-1 that are important for migration (Fig. 7).  Flk-1 mediates VEGF-dependent 
endothelial cell migration, and VEGF/flk-1 signaling affects FAK and Src, molecules 
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involved in focal adhesion signaling and turnover (Abedi and Zachary, 1997; Abu-
Ghazaleh et al., 2001; Gille et al., 2001; Rousseau et al., 2000).  VEGF/flk-1 
signaling also upregulates the activity of the small GTPase Rho (van Nieuw 
Amerongen et al., 2003; Zeng et al., 2002), whose levels and spatial distribution are 
critical to proper migration as well (Ren et al., 2000; Worthylake et al., 2001).  
Indeed, recent work shows that cell migration involves the proper balance of 
adhesion and retraction of a cell, and imbalance in either parameter can impede 
movement (reviews) (Etienne-Manneville and Hall, 2002; Ridley, 2001).  Thus the 
increased flk-1 signaling in flt-1-/- endothelial cells may lead to deregulation of Rho 
and/or focal adhesion turnover and thereby inhibit endothelial cell migration and 
sprout formation.   
 
A model of vascular sprout formation 
Our data is most consistent with a model of vascular sprout formation in which flt-
1 normally negatively regulates the amount of VEGF-A that is available to interact 
with the flk-1 receptor, and this regulation provides the proper balance for a net 
positive effect on sprout formation and migration.  Moreover, we show that the flt-1-/-
morphogenetic defect can be rescued in a non cell-autonomous manner, that sflt-1 
is expressed appropriately to effect this rescue, and that an sflt-1 transgene 
expressed via the PECAM promoter/enhancer can significantly rescue the aberrant 
branching.  Thus, although we cannot exclude a role for surface-localized mflt-1 in 
regulating the availability of VEGF-A, it is likely that sflt-1 is the primary molecular 
mediator of sprout formation from the flt-1 locus (Fig. 7). 
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In our model, sflt-1 is produced by endothelial cells and secreted into the local 
milieu, where it can interact with local sources of VEGF-A.  VEGF-A secretion from 
non-endothelial cells induces migration towards the source of the signal.  It is 
possible that sflt-1 forms a protein gradient emanating from endothelial cells that 
interacts with VEGF-A to set up an effective VEGF gradient, or it could steepen an 
existing gradient (Fig. 7B).  sflt-1 binds heparin via IgG domain 4 (Park and Lee, 
1999), so it may bind the matrix and thus form a gradient.   Alternatively, sflt-1 could 
modulate a pre-existing VEGF-A gradient without forming an independent gradient 
(Fig. 7C).  VEGF-A has three major isoforms that result from alternative splicing, and 
they have different biochemical properties.  The VEGF120 isoform is completely 
diffusible, while the VEGF165 and VEGF188 isoforms are localized to the outer surface 
and surrounding matrix of VEGF-A producing cells, although a significant fraction of 
VEGF165 diffuses from the cell (Park et al., 1993).  Thus these isoforms could 
produce a VEGF-A gradient by virtue of their differing affinities for matrix, and sflt-1 
could impact this gradient.  In this scenario, flt-1-/- mutant endothelial cells are 
inhibited from forming sprouts by exposure to excess VEGF-A (Fig. 7A).  Clearly, flt-
1-/- mutant blood vessels do form sprouts, so while sflt-1 may modulate sprout 
formation and migration, it is not absolutely required for sprouting angiogenesis. 
What is the evidence for this model?  Spatially localized VEGF expression 
predicts branching morphogenesis in the embryonic lung (Healy et al., 2000).  
Analysis of retinal vessels in mouse mutants expressing only a single VEGF isoform 
demonstrates defects in vessel size and number, suggesting that the local 
availability and diffusion of VEGF-A protein is critical for vascular patterning during 
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angiogenesis (Stalmans et al., 2002).  A further analysis of VEGF isoform-selective 
mice provides evidence that a VEGF-A gradient set up in the hindbrain is 
compromised in the absence of matrix-bound VEGF-A (Ruhrberg et al., 2002).  
Moreover, inappropriate amounts of VEGF-A negatively affect sprout formation.  
Exogenous VEGF-A165 injected into quail embryos inhibits the formation and 
branching of intersomitic vessels from the dorsal aorta (Drake and Little, 1995), 
similar to the effects seen in the flt-1-/- mutant embryos in our study.  A recent study 
in the eye showed that increased levels of each VEGF isoform led to reduced 
filopodia length and reduced expansion of the retinal vascular plexus (Gerhardt et 
al., 2003).  These results suggest that excess VEGF-A leads to a perturbed 
endothelial migratory response, perhaps by disruption of a VEGF-A gradient, and 
support a model whereby flt-1 negatively modulates local availability of VEGF-A to 
positively affect sprout formation. 
The use of soluble receptors to modulate the activity of soluble ligands is not 
exclusive to the VEGF-A pathway.  Other growth factors such as FGF, morphogens 
such as Wingless/Wnt, and vascular modifiers such as the angiopoietins, have 
soluble receptors of high affinity that can negatively modulate their respective 
signaling pathways (Guillonneau et al., 1998; Gurdon and Bourillot, 2001; Hanneken 
et al., 1994; Moon et al., 1997; Reusch et al., 2001).  Indeed, the soluble receptor 
Frzb is thought to form gradients that modulate the availability of Wingless to target 
cells (Moon et al., 1997).  Thus, this molecular mechanism of signal regulation is 
conserved in other signaling pathways. 
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Conclusions 
 We have identified a novel role for flt-1 in vascular morphogenesis, as a 
positive regulator of sprout formation and migration.  This role is independent of a 
negative modulatory effect on endothelial cell division.  We propose a model in 
which flt-1 positively affects sprout formation by negatively controlling the amount of 
VEGF-A signal that is sensed by endothelial cells, using sflt-1 as the primary 
mediator of the effect.  We also suggest that gradient formation, either by VEGF-A or 
sflt-1 or both proteins, may be important in modulating sprout formation and 
migration.  In any case, these results have implications for the development of 
disease therapies and for reconstruction of vessels.  Clearly, the local availability of 
VEGF-A signal is critical to proper morphogenesis, and the regulation of this 
availability under normal conditions appears complex.  Thus a better understanding 
of how this is accomplished will allow for better design of regimens for vessel 
reconstitution. 
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Table 1.  Distribution of endothelial cell divisions during sprout formation. 
 
 
                              DAY 6           DAY 8 
               
Location in Vessel WT (23*) flt-1-/- (75) WT (42) flt-1-/- (38)
           Primary Vessel 78% 75% 90% 91% 
           Total Sprout Field 22% 25% 10% 9% 
 Proximal sprout area† 4% 6% 0% 3% 
 Distal sprout area  9% 11% 0% 0% 
 Nascent sprout area  9% 8% 10% 6% 
 
* denotes total number of cell divisions for each genotype. 
† denotes different compartments of the sprout field. 
 43
Figure 1.  GFP expression allows for visualization of mammalian sprouting 
angiogenesis.  Stable ES cell lines expressing PECAM-GFP were generated (see 
Methods) and subjected to time-lapse image analysis of vascular processes for 4.5-
9.5 h.  A) Day 8 WT-eGFP (+/+, a-c) or flt-1-/--eGFP (-/-, d-i) ES differentiation 
cultures were imaged by time-lapse at one min intervals for 4.5-9.5 h, then fixed and 
reacted with an anti-PECAM antibody.  The last frame captured (a, d, g) was 
overlayed (c, f, i) with the PECAM stained image (b, e, h).  B) Time-lapse frames of 
a day 8 WT-eGFP ES differentiation culture showing the formation of a vascular 
sprout and its fusion with another sprout.  Time in min is at lower left of each frame.  
The white arrowhead denotes sprout formation and extension, while the white arrow 
shows the fusion of the sprout tip with the second sprout.  Scale bar in B is 20 µm.  
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Figure 2.  Sprout formation and migration are reduced in the absence of flt-1.  
Day 8 WT-eGFP (+/+, Aa-c, Ca-c) or flt-1-/--eGFP (-/-, Ad-f, Cd-f) ES differentiation 
cultures were imaged by time-lapse at one min intervals for the indicated times.  A) 
Over a 10 h period, numerous new WT sprouts (a-c) formed (white arrowheads) and 
remained or extended and/or fused at later times (black arrowheads), whereas very 
few flt-1-/- sprouts (d-f) formed during the same time period.  Scale bar is 20 µm.  B) 
Movie frames were analyzed to determine a sprout index (#sprouts/mm/hr) for 
multiple movies on day 6 (d6) or day 8 (d8) of differentiation. Grey dots = WT-eGFP 
sprout indices, black dots = flt-1-/--eGFP sprout indices, and black squares with line = 
average of each group.  * = P < 0.03; ** = P < 0.01.  C) Over a 40 min period, a WT 
sprout formed and extended between 30-40 µm, while over a 100 min period a flt-1-/- 
mutant sprout formed and extended only 20 µm.  White arrowheads point to sprout 
tips, and time in min is at lower left.  Scale bar = 20 µm.  D) Movie frames were 
analyzed to determine average sprout velocity (µm/hr) for multiple sprouts from 
different movies on day 8 (d8) of differentiation. Grey dots = WT-eGFP average 
sprout velocities, black dots = flt-1-/--eGFP average sprout velocities, and black 
squares with line = average of each group.  *** = P < 0.001. 
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Figure 3.  Branching morphogenesis is reduced in the absence of flt-1.  Day 8 
WT-eGFP (+/+, Aa-c) or flt-1-/--eGFP (-/-, Ad-f) ES differentiation cultures were fixed 
and reacted with an anti-PECAM antibody.  A) Note that while each genotype had a 
range of branching complexities, on average less complexity was seen in the flt-1-/--
eGFP cultures.  Scale bar is 50 µm.  B) The average number of branch points per 
mm of vessel length was determined using 10 fields of each genotype in 2 
experiments, and expressed as a percentage of wild-type branching.                      
*** = P < 0.001.  
 
 48
 
 
 
 49
Figure 4.  Sprouting from the dorsal aorta is reduced in the absence of flt-1.   
A) 8.5 dpc embryos that were WT (+/+, a-b), flt-1+/- (+/-, c), or flt-1-/- (-/-, d-f), were 
collected and whole mount stained with an anti-PECAM antibody.  a-c), In 3 different 
normal embryos, intersomitic vessels (white arrows) branch from the dorsal aorta 
(black arrowheads).  A magnified view in C shows several intersomitic sprouts (white 
arrowheads) in register posterior to the vessels.  d-f) 2 different flt-1-/- embryos show 
few branches from the dorsal aorta, and those that are seen are often stunted (black 
arrows).  The inset in e and panel f show stunted sprouts with blunted tips.  A = 
anterior, P = posterior.  Original magnification is 5 x.  B) Day 8 WT (a-d) and flt-1-/- 
(e-h) ES differentiation cultures were fixed and stained with a PECAM antibody.  
Representative sprouts were photographed.  Note that most WT sprouts are tapered 
at the distal end (white arrowheads), while most flt-1-/- mutant sprouts are blunted 
(white arrows) at the distal end.  Magnification is 60 x. 
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Figure 5.  Endothelial cell divisions are increased in the absence of flt-1.  Day 6 
WT-eGFP (+/+, A) or flt-1-/--eGFP (-/-, B) ES differentiation cultures were imaged by 
time-lapse at one min intervals for the indicated times.  Day 8 cultures of both 
genotypes were also imaged for quantitation (C).  A-B) Endothelial cell pre-division 
rounding up is denoted by white arrows, and cytokinesis is denoted by grey arrows.  
Time in min is at the lower left.  Note that over a similar time span there are more 
divisions scored in the flt-1-/- mutant vessels.  Magnification is 20 x. C) Time-lapse 
movies from day 6 WT-eGFP (N=6), day 6 flt-1-/--eGFP (N=8), day 8 WT-eGFP 
(N=8), and day 8 flt-1-/--eGFP (N=8) were analyzed for a mitotic score (# endothelial 
cell divisions/eGFP+ area/hr).  *** = P < 0.001. 
 52
 53
Figure 6.   The flt-1-/- phenotype is partially rescued non cell-autonomously and 
by a sflt-1 transgene.  A) Co-culture analysis.  Day 3 EBs were plated in wells so 
that a) 100% were flt-1-/- mutant EBs, or b) 75% were WT and 25% were flt-1-/- 
mutant EBs, and after attachment and incubation for a further 5 days, cultures were 
fixed and stained for β-galactosidase activity.  B) Day 8 WT (Ba-b), flt-1-/- transfected 
with a PECAM-sflt transgene (Bc-d), and flt-1-/- (Be-f) ES differentiation cultures were 
fixed and reacted with an anti-PECAM antibody.  Ba, Bc, Be: 10X exposure; Bb, Bd, 
Bf: 20X exposure.  Note that branching in flt-1-/-PECAM-sflt cultures more closely 
resembles WT than flt-1-/- cultures.    C) The average number of branch points per 
mm of vessel length was determined using multiple fields of each genotype. ** = 
P<0.01, flt-1-/- vs. flt-1-/-PECAM-sflt;   *** = P < 0.001, WT vs. flt-1-/-.  
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Figure 7.  Models of flt-1 modulation of VEGF signal - negative modulation 
results in net positive effect on sprout formation.  We favor a model of flt-1 
action on sprout formation that results from flt-1 binding VEGF-A and preventing 
binding to flk-1 (see text for details).  This could occur in several ways.  A) VEGF-A 
may be deposited in a gradient between the producing tissue and the target vessel, 
and this unmodified gradient is not conducive to sprout formation in the absence of 
flt-1.  B) sflt-1 may be secreted and form a counter-gradient that modifies and 
steepens the VEGF-A gradient, leading to increased sprout formation.  C) mflt-1 
and/or sflt-1 may locally decrease the availability of VEGF-A, leading to increased 
sprout formation.                    
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CHAPTER III 
 
SOLUBLE FLT-1 IS THE PREDOMINANT FLT-1 ISOFORM 
REGULATING VESSEL BRANCHING 
 
 
A. Introduction 
  
Angiogenesis is an important aspect of blood vessel formation, both 
developmentally and in physiological and pathological conditions (Ferrara and 
Alitalo, 1999; Risau, 1997).  During angiogenesis, endothelial cells respond to both 
proliferative signals and morphogenetic cues for vessel sprouting and fusion.  In this 
way, simple vascular structures are extended to form a branching plexus.  Many of 
the factors and pathways important in angiogenesis have been identified, but 
relatively little is known about how signals are regulated to co-ordinate vessel 
branching and endothelial cell proliferation during angiogenesis. 
 The vascular endothelial growth factor-A (VEGF-A) signaling pathway is a 
crucial mediator of angiogenesis (Olsson et al., 2006; Shibuya and Claesson-Welsh, 
2006).  Activation and subsequent signaling via VEGF-A regulates endothelial cell 
division, migration, and survival (Matsumoto and Claesson-Welsh, 2001b).  The 
VEGF-A signaling pathway requires tight dose-dependent regulation for proper 
morphogenesis.  Minor changes in the amount of available VEGF-A adversely affect 
vascular development, and the loss of even one copy of the Vegf-A gene leads to 
embryonic lethality (Bautch et al., 2000; Carmeliet et al., 1996; Damert, 2002; 
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Ferrara et al., 1996; Miquerol et al., 2000).  VEGF-A signaling is further modulated 
by alternative splicing of VEGF-A mRNA to produce three different isoforms (Ng et 
al., 2001b; Park et al., 1993; Tischer et al., 1991).  These VEGF-A isoforms have 
differing affinities for heparin, and therefore are predicted to be distributed 
differentially from VEGF-A-producing cells via differential binding to the extracellular 
matrix.  Genetic manipulations that lead to expression of only the VEGF-A120 or the 
VEGF-A188 isoform from the VEGF-A locus result in vessel dysmorphogenesis 
(Ruhrberg et al., 2002; Stalmans et al., 2002).  Mice that express only the VEGF-
A120 isoform, which does not bind heparin, develop to term, but the hindbrain vessels 
have fewer branches and increased diameter.  In contrast, mice expressing only the 
VEGF-A188 isoform, which has two heparin binding sites, have ectopic vessel 
branches that are long and thin (Ruhrberg et al., 2002).  Recent elegant studies by 
Gerhardt et al. (2003) in the retina support a model in which the spatial context of 
VEGF-A presentation to the endothelial cell is important for vessel morphogenesis, 
while endothelial cell proliferation is regulated by the local VEGF-A concentration in 
a spatially-independent manner (Gerhardt et al., 2003). 
 The biological effects of VEGF-A are mediated by two high affinity receptor 
tyrosine kinases, flk-1 (VEGFR-2) and flt-1 (VEGFR-1), that are expressed on 
endothelial cells.  VEGF-A signaling through flk-1 positively regulates endothelial cell 
division and migration (Dayanir et al., 2001; Gerhardt et al., 2003; Guo et al., 1995; 
Kroll and Waltenberger, 1997; Zeng et al., 2001), whereas the function of flt-1 is less 
clear.  Deletion of flt-1 in embryoid bodies or in vivo results in embryonic lethality at 
mid-gestation, with disorganized blood vessels and over-proliferation of endothelial 
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cells (Fong et al., 1995; Kearney et al., 2002).  Flt-1 mRNA is alternatively spliced to 
encode both a full-length receptor tyrosine kinase (mflt-1) and a soluble isoform (sflt-
1) that contains the VEGF-A-binding extracellular domain (Kendall and Thomas, 
1993; Kendall et al., 1996).  VEGF-A has a higher affinity for flt-1 than for flk-1, so 
both flt-1 isoforms can potentially sequester VEGF-A and modulate signaling 
through flk-1 (Kondo et al., 1998; Park et al., 1994).  Flt-1-/- ES cell-derived vessels 
have approximately 3-fold higher levels of activated flk-1 than do normal vessels, 
consistent with a role for flt-1 in ligand sequestration (Roberts et al., 2004).  Mice 
lacking the cytoplasmic tail of the flt-1 receptor are viable, indicating that the 
signaling function of the flt-1 receptor is not essential during embryonic development 
(Hiratsuka et al., 1998).  A recent study identified a single amino acid in the kinase 
domain of flt-1 that severely reduces kinase activity and signaling (Meyer et al., 
2006),  and the intracellular juxtamembrane region of flt-1 suppressed VEGF-A-
dependent activation of PI 3’-kinase and subsequent endothelial cell migration (Gille 
et al., 2000). Taken together, this data suggests that flt-1 functions in vascular 
development as a ligand sink to bind and sequester VEGF-A, and thus regulate 
signaling through the flk-1 receptor. 
We previously showed that flt-1 regulates both endothelial cell proliferation 
and vessel branching (Kearney et al., 2002; Kearney et al., 2004), but the 
mechanisms underlying this regulation were unclear.  We hypothesized that flt-1, 
through its two isoforms, can modify both the level and presentation of VEGF-A to 
endothelial cells in forming vessels.  To test this model, we reintroduced isoform-
specific flt-1 transgenes into flt-1-/- stem cell-derived vessels.  We confirmed that 
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signaling through flt-1 is not essential for proper vascular development, and we 
found soluble flt-1 to be more effective at rescuing branching morphogenesis, while 
both membrane-tethered and soluble flt-1 rescued endothelial cell proliferation.  
Thus, the ability of soluble flt-1 to disseminate from the endothelial cell appears 
critical to efficient regulation of morphogenesis, whereas both flt-1 isoforms have the 
ability to regulate endothelial cell proliferation. 
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B.  Materials and Methods 
Cell culture and in vitro differentiation 
Wild-type (WT) ES cells, flt-1-/- ES cells, and flt-1-/- ES cells containing a sflt-1 
or mflt-1 transgene under the transcriptional control of the platelet endothelial cell 
adhesion molecule (PECAM) promoter/intron enhancer element (Tg PECAM-sflt-1 
and Tg PECAM-mflt-1) were maintained and differentiated as described previously 
(Bautch, 2002; Bautch et al., 1996).  Embryoid bodies (EBs) were plated onto either 
slide flasks (Nunc, Rochester, NY), or wells of a 24-well tissue culture dish at day 3 
of differentiation and cultured at 37oC in 5% CO2 until day 8, when cultures were 
fixed and analyzed.   
 
DNA constructs and electroporation 
 The PECAM promoter/intron enhancer (gift of P. Robson and H.S. Baldwin) 
was linked to flt-1 cDNAs: sflt-1 (Kearney et al., 2004); mflt-1 (gift of G. Breier; Breier 
et al, 1995); or mflt-1∆Cyt.  The mflt-1 cDNA was first subcloned into the pBluescript 
vector, digested with MluI, blunted, then digested with SalI.  This fragment was 
cloned into a PECAM-Hygro vector via SalI and a blunted NotI site and designated 
PECAM-mFlt-1-Hygro. The mflt-1∆Cyt cDNA was created by amplifying mFlt-1 using 
the following primers: forward primer 5’ 
ACGCGTCGACAGCGCGGAGGCGGACACTCCCGGGAG 3’; reverse primer 5’ 
CCCAAGCTTTATCATATCTTCTGTTTTCTTACCCGCTTCAGTTTTCTGATG 3’.  
The PCR product was digested with SalI and HindIII, while the 3’ UTR was obtained 
by digesting pBluescript-mFlt-1 with HindIII and NotI.  The two fragments were 
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ligated together via HindIII and cloned into the PECAM-Hygro vector and designated 
PECAM-mFlt-1∆Cyt-Hygro. 
 Fifteen µg of linearized DNA was electroporated into 2 X 107 flt-1-/- ES cells 
using a BioRad GenePulser II electroporator (250V/300µF; BioRad, Hurcules, CA.)  
Selection of flt-1-/- ES cells was in 200 µg/mL hygromycin B (Roche Diagnostics, 
Indianapolis, IN).  After 12-14 days, drug-resistant ES cell colonies were picked, 
expanded, and analyzed.  Thirty-five flt-1-/- transgenic lines containing PECAM-sFlt-
1-Hygro (designated at flt-1-/-; Tg PECAM-sflt-1), 25 flt-1-/- transgenic lines containing 
PECAM-mFlt-1-Hygro (designated at flt-1-/-; Tg PECAM-mflt-1), and 30 transgenic lines 
containing PECAM-mFlt-1∆Cyt (designated at flt-1-/-; Tg PECAM-mflt-1∆Cyt) were picked and 
analyzed further.  
Targeted insertion of flt-1 isoform transgene into the ROSA26 genomic locus 
was carried out using Gateway MultiSite cloning vectors.  The targeting vector, 
pROSA26-1 (gift of Phil Soriano) was modified by adding an MluI site into the lone 
restriction site of the MCS, XbaI.  PacI was also added into the KpnI site of 
pROSA26-1.  The resulting vector was designated Modified pROSA26-1.  Modified 
pROSA26-1 was next transformed into a Gateway destination vector by amplifying 
pDEST R4-R3 (with flanking MluI sites) using the following primers: forward primer 
5’ CGACGCGTCAGGAAACAGCTATGAC 3’; reverse primer 5’ 
CGACGCGTTGTAAAACGACGGCCA 3’.  pDEST R4-R3 was then cloned into 
Modified pROSA26-1 using MluI to create pROSA26-1+DEST R4-R3.  Three 
Gateway donor vectors were subsequently created. The first one, pDONR P2R-P3, 
was made as two different vectors; one containing sflt-1 cDNA, and the other 
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containing mflt-1 cDNA.  Each flt-1 transgene and polyadenylation site was amplified 
using the following primers: forward primer 5’ GGGGACAGCTTTCTTG 
TACAAAGTGAGCGCGGAGGCGGACACTCC 3’; reverse primer 5’ GGGGACAA 
CTTTGTATAATAAAGTTGCAGTGAAAAAAATG CTTTATTTGTG 3’.  Each PCR 
product (sflt-1 and mflt-1 transgene) was recombined into pDONR P2R-P3 via attB 
sites to create: pDONR P2R-P3-sflt-1 and pDONR P2R-P3-mflt-1.  The PECAM 
promoter/intron enhancer was then amplified using the following primers: forward 
primer 5’ GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGA GCTCT 
CTATGCTAATGAGG 3’; reverse primer 5’ GGGGACCACTTTGTACAA GAAAGC 
TGGGTAGCTCTGTAATTTTCCTGAVAATGG 3’. The PCR product was recombined 
into pDONR-221 via attB sites to create pDONR221-PECAM.  We next amplified a 
PGK-Hygromycin cassette using the following primers: forward primer 5’ 
GGGGACAACTTGTATAGAAAAGTTGCCTCGAGGTCGATA TCG 3’; reverse 
primer 5’ GGGGACTGCTT TTTTGTACAAACTTGGATCCCCC 
GGGCTGCAGGAATTC 3’. The PCR product was recombined into pDONR P4-P1R 
via attB sites to create pDONR P4-P1R-PGK-Hygro.  Each flt-1 isoform-specific 
pDONR-P2R-P3-flt-1 vector was combined with pDONR221-PECAM, pDONR-P4-
P1R-PGK-Hygro, and pROSA26-1+DEST R4-R3 to create pROSA26-1-PECAM-sflt-
1-Hygro and pROSA26-1-PECAM-mflt-1-Hygro.   
Each pROSA26-1-PECAM-flt-1-Hygro DNA was linearized with PacI and 
electroporated into flt-1-/- ES cells as described above.  Resistant ES clones were 
picked and verified for correct targeting into the ROSA26 locus via PCR using the 
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following primers: forward primer 5’ CCTAAAGAAGAGGCTGTGCT TTGG 3’; 
reverse primer 5’ CCGATGGCTGTGTAGAAGTACTC 3’.   
 
Antibody staining 
Day 8 ES cell cultures were rinsed with phosphate-buffered saline (PBS) and 
fixed for 5 minutes in ice-cold methanol-acetone (50:50).  Fixed cultures were 
reacted with rat anti-mouse PECAM at 1:1000 (MEC 13.3; BD Pharmingen, San 
Diego, CA) and donkey anti-rat immunoglobulin G (IgG; H+L) conjugated to TRITC 
at 1:100 (Jackson Immunoresearch, West Grove, PA).  Alternatively, Alexa Fluor 
488 goat anti-rat (IgG; H+L) at 1:200 (Molecular Probes-Invitrogen) was used, as 
described previously (Bautch et al., 2000).  Cultures were viewed and photographed 
with either an Olympus IX-50 inverted microscope (Melville, NY) outfitted with 
epifluorescence, or with a Leica inverted DMIRB microscope (Bannockburn, IL) and 
a Hamamatsu OrcaER CCD camera (McHenry ,IL). 
 
Quantitative image analysis  
To quantify the area labeled with PECAM antibody in differentiated ES cell  
cultures, fixed cultures were reacted with PECAM antibody, photographed, and 
analyzed as described (Kearney et al., 2002).  Percent PECAM area averages for 
each well were calculated, and the average of 4 wells for each clone was used to 
determine SD values.  Branch point analysis was done on fixed cultures reacted with 
PECAM antibody as described (Kearney et al., 2004).  The average branch point 
score from 8-12 pictures for each clone was used to determine SD values. 
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RNA analysis 
For RT-PCR, total RNA was prepared using Trizol reagent (Invitrogen, 
Carlsbad, CA) according to the manufactures instructions.  Ten µg of total RNA was 
digested with DNase I (Promega, Madison, WI), and 2 µg of DNase-treated total 
RNA was in vitro transcribed with Superscript II reverse transcriptase (Invitrogen) in 
a total volume of 80 µl. 10 µl of the reaction was used for PCR experiments. Taq 
polymerase (Qiagen, Valencia, CA) was used to amplify cDNA using the following 
primers:  Flt-1 forward 5’ ACA CCG CGG TCT TGC CTT AC 3’; Flt-1 reverse 5’ CAG 
CCT TTT GTC CTC CTG GC 3’, Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) Forward 5’ AGC CCA TCA CCA TCT TCC 3’; GAPDH reverse 5’ GCC 
ATC CAC AGT CTT CTG G 3’.  PCR reactions were performed for 3 min at 95oC, 
followed by 30 cycles of 1 min at 95oC, 1 min at 59oC, and 1 min at 72oC.  The PCR 
products were electrophoresed on a 3% agarose gel and detected with ethidium 
bromide.    
 For real-time PCR, total RNA was isolated using Trizol reagent and stored at -
20oC.  PCR primers and fluorogenic probes for the target genes were designed by 
Dr. Hyung-Suk Kim at the University of North Carolina-Chapel Hill Animal Clinical 
Chemistry and Gene Expression Facility.  Sequences of the primer/probe pairs used 
are as follows: Flt-1 forward  5’ ACA CCG CGG TCT TGC CTT AC 3’; Flt-1 reverse 
5’ TTT AAC TTC GAC CCT GAG CCA 3’; Flt-1 probe 5’ f-CT GCT CGG GTG TCT 
GCT TCT CAC-Q 3’, β-actin forward 5’ CTG CCT GAC GGC CAG GTC 3’; β-actin 
reverse 5’ CAA GAA GGA AGG CTG GAA AAG A 3’; β-actin probe 5’ f-CA CTA 
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TTG GCA ACG AGC GGT TCC G-Q 3’ (f, reporter dye, FAM (6-carboxyfluorescein); 
Q, quencher dye, TAMRA (6-carboxytetramethyl-rhodamine).  Relative levels of 
RNA for flt-1 and β-actin were determined by performing real time RT-PCR in a 96-
well plate in a total volume of 30 µl.  Each RT-PCR amplification was performed in 
triplicate: 30 min at 48oC for the RT reaction, then 10 min at 95oC, followed by 40 
temperature cycles (15 sec at 95oC and 1 min at 60oC).  During the amplification, the 
fluorescence of FAM was measured with the ABI Prism 7700 Sequence Detection 
System (PE Biosystems Inc.) at the UNC-Chapel Hill Animal Clinical Chemistry and 
Gene Expression Facility.  The threshold cycle (CT) value of each target product was 
determined and normalized to its corresponding β-actin CT value.  The relative 
quantitative results were used to determine the difference in flt-1 expression in 
experimental ES cell cultures compared to WT flt-1 RNA. 
 
In situ hybridization 
 
 Flt-1 antisense RNA probe labeled with digoxigenin-UTP (Boehringer, 
Mannheim, Germany) was synthesized by reverse transcription of a 1.6 kb PvuII 
fragment which was derived from the 5’ end of flt-1 cDNA and subcloned into 
pBluescript KS II (gift from Gua-Hua Fong).  In situ hybridization was performed  by 
modification of a standard protocol used for whole-mount hybridization (Rosen and 
Beddington, 1993) as described previously (Bautch et al., 2000).  After in situ 
hybridization of day 8 differentiated cultures, samples were viewed and 
photographed with an Olympus IX-50 inverted microscope. 
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C.  Results 
Transgenes encoding individual flt-1 isoforms rescue the flt-1-/- vessel 
phenotype 
ES cell-derived vessels lacking flt-1 have an increased endothelial cell mitotic 
index (Kearney et al., 2002), and a morphogenetic defect that results in reduced 
sprouting and branch formation (Kearney et al., 2004).  To directly assess the role of 
the flt-1 isoforms on endothelial cell division and vessel morphogenesis, we 
generated clones carrying flt-1 cDNA transgenes (Fig. 8A; sflt-1, mflt-1, or mflt-1∆Cyt) 
randomly integrated into the genome of flt-1-/- ES cells.  The transgenes were linked 
to the PECAM promoter/enhancer because it results in expression of transgenes in 
developing blood vessels (Kearney et al., 2004).  After electroporation and selection, 
flt-1-/-; Tg PECAM-flt-1 ES cell clones were differentiated to day 8, then labeled with 
PECAM antibody to visualize vessel area and morphology, or processed for RNA 
isolation (Fig. 8B).  flt-1-/-; Tg PECAM-flt-1 ES cell clones that were positive for flt-1 RNA 
by RT-PCR (data not shown) were used for further analysis.  
Flt-1-/-; Tg PECAM- flt-1 vessels exhibited a range of vascular phenotypes 
compared to flt-1-/- vessels.  Clones with vessels that were visually indistinguishable 
from flt-1-/- vessels were categorized as having no rescue (Fig. 8C, F, I, Table 2).  A 
second group of clones showed primarily a rescue of vessel morphogenesis (Fig. 
8D, G, J, Table 2), and areas of endothelial sheets seen in flt-1 mutant cultures were 
replaced with areas of branched vascular plexus.  A third group of clones had 
primarily a rescue of endothelial cell proliferation (Fig. 8E, H, K, Table 2), with an 
overall reduction of vascular area, but little or no rescue of morphogenesis.  
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80% of flt-1-/-; Tg PECAM-sflt-1 clones had primarily a rescue of vessel 
morphogenesis (Table 2).  In contrast, only 16% of flt-1-/-; Tg PECAM-mflt-1 clones had a 
primary morphogenesis rescue (Table 2).  All of the flt-1-/-; Tg PECAM-sflt-1 clones 
showed some type of rescue, whereas 63% of flt-1-/-; Tg PECAM-mflt-1 clones (Table 2) 
were not rescued.  Finally, a similar percentage of both flt-1-/-; Tg PECAM-sflt-1 and flt-1-/-; 
Tg PECAM-mflt-1 clones had primarily a proliferation rescue, 20% and 21%, respectively 
(Table 2).  These data suggest that the sflt-1 transgene rescues vessel branching 
morphogenesis more efficiently than the mflt-1 transgene, and that the transgenes 
rescue endothelial proliferation with equivalent efficiency. 
We next quantitated the rescue of vessel morphogenesis in a subset of 
clones using a branch point analysis.  Day 8 cultures of WT, flt-1-/-, and two clones 
each of flt-1-/-; Tg PECAM-sflt-1 and flt-1-/-; Tg PECAM-mflt-1 genotype labeled with PECAM 
were analyzed (Fig. 9).  Flt-1-/- cultures, as previously described (Kearney et al., 
2004), had a 30% decrease in branch point formation relative to WT.  Vessels of 
clones that express sflt-1 or mflt-1 transgenes, and were categorized as a Primary 
Morphogenesis rescue, had a higher branch point score (# branch points/mm vessel 
length) than flt-1-/- vessels (Fig. 9B-F, G).  Thus, clones grouped as a Primary 
Morphogenesis rescue by visual analysis also had elevated branch point scores, 
although no rescued clones attained the branch point score of WT vessels. 
 
To quantitate the rescue of endothelial cell proliferation in the clones 
expressing flt-1 isoform transgenes, we calculated the amount of vasculature as 
measured by the percentage of the cellular area that was positive for PECAM-1 
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antibody reactivity.  We previously showed that this parameter reflects the number of 
endothelial cells, and that it is increased in flt-1 mutant vessels because of an 
increase in the endothelial mitotic index (Kearney et al., 2002).  Two clones, scored 
as a primary rescue of proliferation by visual observation (flt-1-/-; Tg PECAM-mflt-1#26 and  
flt-1-/-; Tg PECAM-sflt-1#2), had a percent vascular area of 24% and 28%, respectively, 
which was near the WT value of 22% (Fig. 10).  Flt-1-/- cultures had a vascular area 
of 67%, which was a 3-fold increase in vascular area relative to WT, and consistent 
with previously published data (Fig. 10; (Kearney et al., 2002).  Two flt-1-/-; Tg PECAM-
mflt-1 clones (flt-1-/-; Tg PECAM-mflt-1#13 and  flt-1-/-; Tg PECAM-mflt-1#1), which are phenotypically 
indistinguishable from flt-1-/- cultures, had vascular areas of 73% and 78%, 
respectively, which were similar to the flt-1-/- value (Fig. 10).  Thus, clones placed in 
the No Rescue category by visual observation also belong there by quantitative 
criteria.  Interestingly, 5 of the 6 clones grouped as primarily a morphogenesis 
rescue had vascular area values that fell between WT and flt-1-/- cultures (Fig. 10).  
Thus, although these clones primarily show a rescue of morphogenesis, they also 
have a partial rescue of vascular area.  
 
Expression profile of flt-1 isoform transgene-expressing clones  
Electroporation of PECAM-flt-1 isoform DNA into flt-1-/- ES cells yielded ES 
cell clones with flt-1 isoform transgenes integrated randomly at different genomic 
locations.  Random integration of transgenes leads to expression that can differ 
temporally, spatially, and quantitatively among integration sites (Palmiter and 
Brinster, 1986). To determine if the phenotypic differences seen among the rescue 
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clones correlated with differences in flt-1 isoform transgene expression, we analyzed 
transgene expression parameters in representative rescue clones.  Total RNA was 
collected from WT, flt-1-/-, flt-1-/-; Tg PECAM-sflt-1 and  flt-1-/-; Tg PECAM-mflt-1 ES cell cultures 
at the ES cell stage and every two days during differentiation, and analyzed by RT-
PCR using flt-1-specific primers to obtain a developmental expression profile.  Flt-1 
was detected throughout the time-course in WT controls, and it was not detected in 
flt-1-/- cultures.  Similar to WT, all flt-1 isoform transgene clones tested (6 sflt-1 
isoform rescue clones and 6 mflt-1 isoform rescue clones) had detectable flt-1 RNA 
throughout the time-course (Fig. 11 and data not shown).   
We next asked whether phenotypic differences among the flt-1 isoform 
expressing ES cell cultures correlated with differences in the location of transgene 
expression. Day 8 WT, flt-1-/-, and representative flt-1-/-; Tg PECAM-sflt-1 and flt-1-/-; Tg 
PECAM-mflt-1 cultures were analyzed by in situ hybridization with an anti-sense probe to 
flt-1.  All flt-1 isoform cultures expressed flt-1 RNA in vessels, albeit at reduced 
levels compared to the WT control (Fig. 12 and data not shown).  Taken together, 
these data suggest that the different phenotypes observed among the flt-1 isoform-
expressing cultures are not due to differences in the timing and localization of 
transgene expression. 
 We used real-time PCR to quantitate the level of flt-1 isoform transgene 
expression in representative flt-1 isoform expressing ES cell cultures.  Flt-1 RNA 
levels were normalized to β-actin and expressed as a percentage of WT flt-1 RNA 
(Fig. 13).  Levels of flt-1 isoform transgene RNA varied among the cultures.  
Moreover, the levels of flt-1 isoform RNA correlated with the vascular phenotype, 
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with the categories of No Rescue, Primary Morphogenesis Rescue, and Primary 
Proliferation Rescue roughly corresponding to increasing levels of transgene RNA.  
However, isoform-specific differences were also noted.  The enhanced ability of the 
sflt-1 transgene to rescue morphogenesis (Table 2) does not appear to result from 
increased levels of sflt-1 transgene RNA, since all of the sflt-1 isoform-expressing 
clones that primarily rescued vascular morphogenesis had lower levels of transgene 
RNA than the few comparable mflt-1 clones.  Moreover, two flt-1-/-; Tg PECAM-mflt-1 
cultures that did not rescue the vascular phenotype had transgene RNA levels 
comparable to the levels of several flt-1-/-; Tg PECAM-sflt-1 clones that rescued vessel 
morphogenesis (Fig. 13: flt-1-/-; Tg PECAM-mflt-1#1 = 2.0%, flt-1-/-; Tg PECAM-mflt-1#13= 7.9% 
versus flt-1-/-; Tg PECAM-sflt-1#27= 1.3%,  flt-1-/-; Tg PECAM-sflt-1#23= 6.7%, flt-1-/-; Tg PECAM-sflt-
1#33= 8.7%, flt-1-/-; Tg PECAM-sflt-1#26= 11.7%).  Thus, levels of mflt-1 transgene RNA that 
did not elicit a rescue response were sufficient to rescue morphogenesis if the 
isoform transgene was sflt-1.  A low percentage of mflt-1 transgenes rescued vessel 
morphology and significantly higher levels of mflt-1 RNA were required to elicit that 
response (Fig. 13: flt-1-/-; Tg PECAM-mflt-1#8= 20.7% and flt-1-/-; Tg PECAM-mflt-1#17= 30.6%  
compared to sflt-1-expressing clones; 1.3%-11.7%).  This trend continued when 
comparing sflt-1 and mflt-1-expressing clones that rescue proliferation.  Flt-1-/-; Tg 
PECAM-sflt-1#2  is rescued to the same degree as flt-1-/-; Tg PECAM-mflt-1#26 (Fig. 8 D, G and 
Fig. 10), however, a 3.5-fold increase in mflt-1 RNA compared to sflt-1 RNA is 
required for this rescue (Fig. 13 flt-1-/-; Tg PECAM-sflt-1#2= 18.3% versus flt-1-/-; Tg PECAM-mflt-
1#26= 65.0%).  These data suggest that the sflt-1 isoform rescues the flt-1-/- 
phenotype more efficiently than the mflt-1 isoform. 
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The cytoplasmic domain of mflt-1 is not required for flt-1 to rescue the flt-1-/- 
vascular phenotype 
To determine if signaling is important in the observed rescue of either 
endothelial proliferation or vessel morphogenesis by mflt-1, we introduced a flt-1 
transgene lacking the cytoplasmic domain (mflt-1∆Cyt) into flt-1-/- ES cells (Fig. 8).  
The mflt-1∆Cyt isoform transgene used in this study encoded the same amino acids 
as the flt-1 allele used to conclude that signaling via flt-1 is not required for normal 
development and angiogenesis in vivo (Hiratsuka et al., 1998).  flt-1-/-; Tg PECAM-mflt-1∆Cyt 
clones rescue vessel branching and cell proliferation as effectively as full-length flt-1 
(Fig. 8I, J, K, table 1), suggesting that signaling through flt-1 is not required to rescue 
either proliferation or morphogenesis of the flt-1-/- vascular vessels. 
 
Genetic targeting of flt-1 isoform transgenes into the ROSA26 locus: sflt-1 
rescues branching morphogenesis more efficiently than mflt-1. 
Random integration of flt-1 isoform transgenes into flt-1-/- ES cells resulted in 
a range of transgene expression levels and phenotypes among rescue cultures 
expressing the same flt-1 isoform.  To more directly compare the effects of the 
isoforms, we targeted the sflt-1 and mflt-1 isoform transgenes into the ROSA26 
genomic locus.  Attempts to target DNA into the ROSA26 locus of ES cells have 
been described previously and have proved successful in avoiding complications 
regarding expression differences due to variation in transgene copy number and 
integration site (Soriano, 1999) (Srinivas et al., 2001).  Targeting constructs were 
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generated and electroporated into flt-1-/- ES cells (Fig. 14A).  Resistant flt-1-/- ES 
colonies were differentiated, correct targeting by homologous recombination was 
verified by PCR, and expression of individual flt-1 isoform transgenes was verified by 
RT-PCR (data not shown).  Day 8 cultures of one clone each of flt-1-/-; Tg ROSA26-PECAM-
sflt-1 and flt-1-/-; Tg ROSA26-PECAM-mflt-1 genotype labeled with PECAM were initially 
analyzed (Fig. 14B-C).  Vessels that expressed the sflt-1 isoform transgene had an 
increase in vascular branching complexity compared to vessels that expressed the 
mflt-1 isoform transgene, and endothelial cell proliferation appeared to be rescued to 
similar levels in vessels of both cultures.  This preliminary data corroborates our 
initial clonal analysis and supports a model in which the soluble isoform of flt-1 
rescues branching morphogenesis more efficiently than the membrane-tethered flt-1 
isoform.  
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D.  Discussion 
Our results show that the soluble flt-1 isoform rescues the vessel branching 
morphogenesis defect observed in flt-1-/- ES cell-derived vessels (Kearney et al., 
2004), and that it does so more efficiently than the membrane-tethered flt-1 isoform.  
In support of this conclusion, 80% of flt-1-/-; Tg PECAM-sflt-1 clones rescue branching 
morphogenesis, whereas only 16% of flt-1-/-; Tg PECAM-mflt-1 clones rescue the flt-1-/- 
branching defect.  Expression analysis revealed that lower levels of sflt-1 transgene 
RNA are sufficient to rescue morphogenesis compared to the few mflt-1- expressing 
clones.  Furthermore, genetic targeting of the flt-1 isoform transgenes into the 
ROSA26 genomic locus of flt-1-/- ES cells shows that sflt-1 contributes to more 
complex vascular branching than mflt-1.  This data supports a model whereby flt-1 
primarily affects vascular branching morphogenesis via a soluble molecule, sflt-1 
(Fig. 15).  This indicates that the modulation of VEGF-A presentation to endothelial 
cells via sflt-1 is important for proper vascular morphogenesis. 
 What is the evidence for this model?  VEGF-A RNA is alternatively spliced to 
produce multiple VEGF-A isoforms.  Due to the differing affinities of the three major 
VEGF-A isoforms (VEGF-A120, VEGF-A164, VEGF-A188) to bind heparin, it is 
hypothesized that their spatial distribution in the extracellular matrix regulates vessel 
patterning and morphogenesis, as illustrated in the embryonic lung (Healy et al., 
2000).  Evidence for this hypothesis comes from analysis of retinal vessels in mouse 
mutants expressing only a single VEGF-A isoform.  Mice expressing either VEGF-
A120, which lacks a heparin-binding domain, or VEGF-A188, with multiple heparin 
binding domains, have retinas with perturbed migration of vascular tip cell filopodia, 
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reduced expansion of the retinal vascular plexus, and vessels with aberrant 
morphogenesis (Ruhrberg et al., 2002) (Gerhardt et al., 2003).  Furthermore, 
analysis of VEGF-A isoform-selective mice provides evidence that a VEGF-A 
gradient set up in the hindbrain is compromised in the absence of matrix-bound 
VEGF-A, resulting in reduced vascular branching (Ruhrberg et al., 2002).  Thus, it is 
thought that a proper distribution of VEGF-A is required for correct regulation of 
vascular morphogenesis.   
Our data indicates that sflt-1, secreted from endothelial cells, interacts with 
VEGF-A to modulate its presentation to endothelial cells in a way important for 
proper morphogenesis.  sflt-1 contains a heparin-binding domain (Park and Lee, 
1999), so it likely binds the extracellular matrix upon release from the endothelial 
cell.  The secreted flt-1 could spread uniformly from the endothelial cell and regulate 
in a quantitative fashion the presentation of VEGF-A which is already established.  
Alternatively, sflt-1 might establish a counter-gradient that could modulate VEGF-A 
presentation to endothelial cells qualitatively as well, and this counter-gradient could 
steepen an existing VEGF-A gradient.  How might this happen?  VEGF-A protein 
has been observed to migrate over several cell distances from the hindbrain midline 
to establish a VEGF-A gradient (Ruhrberg et al., 2002).  It is possible that sflt-1 can 
do this as well. Preliminary studies in quail embryos have suggested that sflt-1 may 
travel over several cell diameters to modulate VEGF-A, and affect the ingression of 
vessels into the neural tube from the peri-neural vascular plexus (J.M.J. and V.L.B., 
unpublished results).  Thus, it is possible that sflt-1 is secreted into the outside 
environment and moves some distance from the vessel, where it can modulate 
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VEGF-A presentation for efficient control of vascular branching morphogenesis (Fig. 
15).   
We have observed that filopodia, which predominantly form from the tips of 
growing vascular sprouts, can extend 1-2 cell lengths into the extracellular matrix.  
Analysis of retinal vessels suggest that the tip cells that extend these filopodia, 
express higher than normal levels of flk-1, implicating these cells as sensors of 
positional information (Gerhardt et al., 2003).  Thus, it is possible that the filopodia 
emanating from a migrating sprout can detect VEGF-A and subsequently transmit a 
signal to begin a branching response; which may include polarizing the endothelial 
cell, followed by enablement of active migration/elongation of the sprout.  Therefore, 
if there is perturbed presentation of VEGF-A to the sensing sprout tip, deregulation 
of branching morphogenesis may follow.  Filopodia have also been implicated in 
sensory roles in other systems, such as in the neuronal growth cone, where filopodia 
are thought to guide the growing axon by sensing extracellular cues.  In Drosophila, 
filopodia are extended from terminal branches of tracheal cells in response to FGF 
from oxygen-deprived cells (Sutherland et al., 1996). 
In the present study, while all flt-1-/-; Tg PECAM-sflt-1 clones subjected to branch 
point analysis partially rescued the flt-1-/- branching defect, no flt-1-/-; Tg PECAM-sflt-1 
clone fully restored vascular branch scores to WT levels.  It is possible that the 
reason for the lack of complete rescue in these clones is due to an incomplete flt-1 
gradient in the absence of mflt-1.  While sflt-1 may be important for modulating 
VEGF-A at a distance from the vessel, there may be a requirement for mflt-1 to be 
expressed on the endothelial cell membrane so as to begin the formation of a flt-1 
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gradient.  It is also a possibility that the PECAM promoter used to express the 
individual flt-1 isoform transgenes does not exactly recapitulate flt-1 expression, 
leading to inappropriate production of sflt-1, and thus, not a full rescue of the flt-1-/- 
branching defect. 
Although most of the flt-1-/-; Tg PECAM-sflt-1 clones primarily rescued 
morphogenesis (80%; Table 2), only a small minority of flt-1-/-; Tg PECAM-mflt-1 clones did 
so (16%; Table 2).  The reduced ability of the flt-1-/-; Tg PECAM-mflt-1 clones to primarily 
rescue morphogenesis is likely due to the flt-1 receptor being anchored to the 
endothelial cell surface.  In these clones, mflt-1 is not free to diffuse into the local 
milieu, where it can interact with sources of VEGF-A to efficiently modulate 
branching morphogenesis.  There were, however, exceptions to this, since 16% of 
flt-1-/-; Tg PECAM-mflt-1 clones partially rescued the flt-1-/- branching defect.  It is possible 
that ectopic expression of the mflt-1 transgene led to the primary morphogenesis 
phenotype.  While mflt-1 isoform transgene expression was predominantly limited to 
the vessels (Fig. 12), we did observe some ectopic mflt-1 isoform transgene 
expression outside of the vasculature in these clones (data not shown).  Thus, it is 
possible that minor amounts of avascular expression of mflt-1 can modulate VEGF-A 
presentation for efficient rescue of morphogenesis.  It is also a formal possibility that 
the mflt-1 protein produced in these clones is being proteolytically cleaved from the 
endothelial cell membrane, thus mimicking the function of sflt-1.  Immunostaining 
experiments, along with ELISA and/or western analysis will be carried out in the 
future to confirm any of the aforementioned possibilities concerning the efficacy of 
mflt-1 rescuing branching morphogenesis.   
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Our results show that both sflt-1 and mflt-1 can rescue the endothelial cell 
over-proliferation defect observed in flt-1-/-  ES cell-derived vessels (Kearney et al., 
2002; Kearney et al., 2004).  However, the way in which flt-1 rescues endothelial cell 
proliferation is unclear.  Nearly equal numbers of flt-1-/-; Tg PECAM-sflt-1 clones and flt-1-/-; 
Tg PECAM-mflt-1 clones (20% and 21%, respectively; table 2) primarily rescued 
endothelial cell proliferation, suggesting that sflt-1 and mflt-1 isoform transgenes 
rescue proliferation with equivalent efficiency. Preliminary analysis of flt-1-/- ES cell-
derived vessels with a targeted insertion of the flt-1 isoform transgene into the 
ROSA26 locus also indicate that mflt-1 and sflt-1 can rescue proliferation 
equivalently (data not shown).  This is in agreement with other models that suggest 
that the levels of VEGF-A, not distribution, are critical for proper regulation of 
endothelial cell proliferation.  In vitro experiments have shown that endothelial cell 
proliferation is dependent on a local concentration of VEGF-A, and that this 
response is dose-dependent (Cai et al., 2006; Waltenberger et al., 1994).  VEGF-
A120 and VEGF-A165 promoted in vitro endothelial cell proliferation with equal 
efficiency, in a dose-dependent manner (Ruhrberg et al., 2002).  Moreover, studies 
in mouse retinas have shown that cells behind the leading tip cell in a sprout (stalk 
cells) are stimulated to divide in the presence of VEGF-A, regardless of correct 
VEGF-A distribution, suggesting that endothelial cell proliferation is regulated by the 
local VEGF-A concentration in a spatially-independent manner (Gerhardt et al., 
2003).  How may this be occurring?  Although some filopodia do extend from other 
cells within the vessel, most filopodial projections are found on tips of angiogenic 
sprouts.  We and others have observed that the tips of vascular sprouts rarely, if 
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ever, divide.  Therefore, while filopodial projections from sprout tips may be 
important for sensing a VEGF-A environment for proper sprout formation, it is 
possible that filopodia are not required to transmit proliferative signals to the vessel.  
It could be that the cells behind the leading cell in the sprout, which also express flk-
1, divide upon sensing any VEGF-A, regardless of gradient or distribution. Thus, if 
proliferation is not dependent on a gradient of VEGF-A, then it is possible that both 
sflt-1 and mflt-1 are equally efficient in rescuing endothelial cell proliferation in flt-1-/- 
ES cell-derived vessels. 
While it is possible that sflt-1 and mflt-1 are equally efficient in rescuing the 
proliferation defect in flt-1-/- cultures, it is also a possibility that sflt-1 is more efficient 
than mflt-1 in rescuing endothelial cell proliferation.  While sflt-1 and  mflt-1 do 
rescue an equal number of clones in the Primary Proliferation Rescue category, 
vascular area analysis indicates that all flt-1-/-; Tg PECAM-sflt-1 clones that primarily 
rescued morphogenesis had a partial rescue of flt-1-/- vascular area (Fig. 10).  
Although not all of the flt-1-/-; Tg PECAM-sflt-1 clones were analyzed for vascular area, 
personal observation indicates that 100% of  flt-1-/-; Tg PECAM-sflt-1 clones (20/20 sflt-1 
isoform transgene clones: 16/20 Primary Morph. Rescue clones plus 4/20 Primary 
Prolif. Rescue clones; table 2) had some level of proliferation rescue compared to 
only 37% of flt-1-/-; Tg PECAM-mflt-1 clones (7/19 mflt-1 isoform transgene clones: 3/19 
Primary Morph. Rescue clones plus 4/19 Primary Prolif. Rescue clones; table 2).  
Also, real time PCR analysis of flt-1-/-; Tg PECAM-sflt-1#2 and flt-1-/-; Tg PECAM-mflt-1#26 clones 
reveal that less sflt-1 isoform transgene RNA is required to achieve the same 
phenotypic response as mflt-1 (Fig. 13), further suggesting sflt-1 to be more efficient 
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than mflt-1 in rescuing endothelial cell proliferation.  If this is true, then the ability of 
flt-1 to be secreted away from the endothelial cell must also be crucial for regulating 
endothelial cell division.  How may this be occurring? One possibility is that after sflt-
1 modulation of VEGF-A, angiogenic sprouts send out filopodia to receive 
proliferative signals from the external environment.  Since cell divisions are rare at 
the tips of sprouts, there may be a potential block in cell proliferation of sprout tips; 
however, through an unknown mechanism, tip cells might be able to transmit a 
proliferative signal to the rest of the vessel.  Thus, if modulation of VEGF-A 
presentation is an important parameter for sprout tips to sense a proliferative signal, 
then there may be an increased role for sflt-1 in regulating cell proliferation in 
vessels. Alternatively, since we have observed some filopodial extensions radiating 
from non-tip cells, albeit at reduced levels compared to the sprout tip cells, these 
filopodia could be sensing a VEGF-A environment, and upon correct modulation via 
sflt-1, can help to properly modulate endothelial cell division.   
A recent study has suggested that membrane-tethered flt-1 is required 
developmentally for the proper delivery of VEGF-A to the endothelial cell membrane 
(Hiratsuka et al., 2005).  This data is supported by the observation that half of the 
mice that do not express membrane-tethered flt-1 die as embryos due to poor blood 
vessel development.  These results become complicated, as the other half of the 
mice survive.  The conclusion that is reached for a requirement for membrane-
tethered flt-1 becomes even more ambiguous, as 99% of mice lacking membrane-
tethered flt-1 from a 129 genetic background survive.  The authors point to increased 
flk-1 expression (flk-1 phosphorylation levels were not measured) in these mice as 
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the reason for the high survival rate; however, their explanation is not well 
supported.  The mice used in this experiment also express higher than normal levels 
of soluble flt-1, as all RNA transcribed from the locus encodes sflt-1.  Thus excess 
levels of sflt-1, which can sequester VEGF-A, could be contributing to the 50% 
lethality observed in these mice, as minor changes in the amount of available VEGF-
A can adversely affect vascular development.  Although these results are 
complicated, the data does indicate that sflt-1 is sufficient for normal vascular 
development in vivo under certain circumstances.  These results suggest that mflt-1 
is not necessary to combine with sflt-1 to create a complete gradient of flt-1.  
Perhaps it is possible that sflt-1 expression alone is sufficient in vivo, even though 
branching morphogenesis may not be completely optimal. 
 
 My data indicates that sflt-1 is more efficient than mflt-1 in rescuing the     
defect of flt-1-/- vessels in branching morphogenesis.  This is especially evident in the 
high percentage of mflt-1 transgene-expressing clones that did not alter the flt-1 
mutant phenotype (62%, table 2).  I have also shown that both sflt-1 and mflt-1 can 
rescue the aberrant endothelial cell proliferation of flt-1 mutant vessels, but it is not 
exactly clear how this is accomplished.  Further analysis of flt-1 isoform targeted 
clones (ROSA 26 locus) may reveal more precisely how flt-1 modulates vascular 
development.
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Figure 8.  Differentiated flt-1-/-; Tg PECAM sFlt-1/mFlt-1/mFlt-1∆cyt ES cell cultures show 
rescue of the flt-1 mutant vessel phenotype.  (A) Map of individual flt-1 isoforms.  
Soluble flt-1 (sflt-1), full length flt-1 (mflt-1), and cytoplasmic-deleted flt-1 (mflt-1∆Cyt) 
each contain an extracellular, VEGF-A-binding domain (grey circles).  mflt-1 and 
mflt-1∆Cyt contain a transmembrane domain region (TM), while only mflt-1 contains a 
tyrosine kinase domain.  (B) A transgene consisting of the PECAM 
promoter/enhancer linked to either sflt-1, mflt-1, or mflt-1∆Cyt cDNA was 
electroporated into flt-1-/- ES cells.  Individual hygromycin B-resistant ES cell clones 
were differentiated to day 8, then stained with PECAM-1 antibody or processed for 
RNA.  (C-K) flt-1-/- ES cell clones expressing a PECAM-sflt-1 transgene (flt-1-/-; Tg 
PECAM-sflt-1) (C-E), a PECAM-mflt-1 transgene (flt-1-/-; Tg PECAM-mflt-1) (F-H), or a PECAM-
mflt-1∆cyt transgene (flt-1-/-; Tg PECAM-mflt-1∆cyt) (I-K) were grouped into 3 categories 
based on visual inspection of vessels: No Rescue (C, F, I), Primary Morphogenesis 
Rescue (D, G, J), or a Primary Proliferation Rescue (E, H, K).  Numbers at upper 
right in panels indicate the clone number. Magnification is 10x.
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Figure 9.  Branch point analysis of Primary Morphogenesis Rescue clones.  (A-
F)  Day 8 differentiated ES cell cultures were reacted with PECAM antibody to 
visualize branched vessels.  WT (A), flt-1-/- (B), flt-1-/-; Tg PECAM-sflt-1 (C-D), and      flt-1-/-
; Tg PECAM-mflt-1 (E-F) cultures are at 10 X magnification.  Note that the rescue clones 
(C-F) have more branching vessels than flt-1-/- vessels (B).  Clone number is in the 
upper right of each panel.  (G) The average number of branch points per mm of 
vessel length was determined.  ***P< 0.001, WT versus flt-1-/-; ***P< 0.001, flt-1-/- 
versus flt-1-/-; Tg PECAM-sflt-1#33; **P< 0.015, flt-1-/- versus flt-1-/-; Tg PECAM-sflt-1#26 and flt-1-/- 
versus flt-1-/-; Tg PECAM-mflt-1#8. 
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Figure 10.  Quantitation of vascular area in flt-1 isoform transgene-expressing 
clones.   
Day 8 differentiated ES cell cultures were analyzed for PECAM-positive area as 
described (see Materials and Methods).  flt-1-/-; Tg PECAM-flt-1 clones are grouped by 
visual vascular phenotypes: No Rescue, Primary Morphogenesis Rescue, and 
Primary Proliferation Rescue.  WT area, white bar; flt-1-/- area, grey bar; flt-1-/- Tg 
PECAM-sflt-1 area, red bars; flt-1-/-; Tg PECAM-mflt-1 area, blue bars.  Clone numbers are 
indicated for each flt-1-/-; Tg PECAM-flt-1 clone (s=flt-1-/-; Tg PECAM-sflt-1; m=flt-1-/-; Tg PECAM-mflt-
1).  *P< 0.004, flt-1-/- versus WT and flt-1 isoform transgene clones. 
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Figure 11.  flt-1-/- ; Tg PECAM- flt-1 clones express flt-1 RNA throughout    
development.  Total RNA was isolated from wild-type (WT), flt-1-/- , flt-1-/-; Tg PECAM-
mflt-1#13, and flt-1-/-; Tg PECAM-sflt-1#2 ES cell cultures at the indicated times: day 0, ES 
cells; day 2, D2; day 4, D4; day 6, D6; day 8, D8; and analyzed by RT-PCR using 
Flt-1 primers (top panels) or GAPDH primers (bottom panels). 
 
 
 90
 
 
 
 
 
 91
Figure 12.  flt-1-/- ; Tg PECAM- flt-1 clones express flt-1 RNA in ES cell-derived 
vessels.   
Day 8 differentiated ES cell cultures were fixed and processed for in situ 
hybridization and hybridized with an antisense flt-1 probe (A-D).  Wild-type (A), flt-1-/- 
(B), flt-1-/-; Tg PECAM-sflt-1#33 (C), and flt-1-/-; Tg PECAM-mflt-1#8 (D) cultures are pictured at 40 
x magnification. 
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Figure 13.  Flt-1 isoform transgene expression levels by real-time PCR 
correlate with flt-1-/- vessel rescue phenotype .  Flt-1 RNA from day 8 ES cell 
cultures was normalized to β-actin RNA and expressed as percentage of wild-type 
flt-1 RNA (100%).  flt-1-/-; Tg PECAM-flt-1 clones are grouped by the rescue phenotype:  
WT, white bar; flt-1-/-, grey bar; flt-1-/-; Tg PECAM-sflt-1 , red bars; and     flt-1-/-; Tg PECAM-mflt-
1, blue bars.  Clone numbers are indicated for each flt-1-/-; Tg PECAM-flt-1 clone (s= flt-1-/-; 
Tg PECAM-sflt-1; m= flt-1-/-; Tg PECAM-mflt-1).  Each real time PCR was performed in triplicate 
and data reflects the average of two experiments performed in triplicate.  *P ≤ 0.05, 
flt-1-/-; Tg PECAM-mflt-1#26 versus flt-1-/-; Tg PECAM-sflt-1#2; **P ≤ 0.001, flt-1-/-; Tg PECAM-mflt-1 
clones versus flt-1-/-; Tg PECAM-sflt-1 clones or flt-1-/-; Tg PECAM-mflt-1 clones versus flt-1-/-. 
 
 94
 
 
 
 
 
 95
Figure 14.  flt-1-/- ; Tg ROSA26-PECAM-sflt-1 clone contains more branched 
vascular networks than flt-1-/- ; Tg ROSA26-PECAM-mflt-1 clone.  (A)  ROSA26 
targeting.  Top, targeting vector containing 5’ and 3’ ROSA26 sequence for 
homologous recombination into genomic locus, PECAM-sflt-1/mflt-1 transgene, 
PGK-Hygro cassette for positive selection, and PGK-DTA for negative selection.  
Middle, ROSA26 genomic locus.  Bottom, targeted insertion of transgene into 
ROSA26 locus.  (B-C)  Day 8 differentiated ES cell cultures were reacted with 
PECAM antibody to visualize branched vessels.  flt-1-/- ; Tg ROSA26-PECAM-sflt-1 
(B) and flt-1-/- ; Tg ROSA26-PECAM-mflt-1 (C) cultures at 10x magnification.  Note 
that sflt-1 isoform-expressing transgene clone (B) has more vascular branching than 
mflt-1 isoform-expressing transgene clone (C). Clone numbers are indicated in 
upper right corner of each image. 
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Figure 15.  sflt-1 more efficient than mflt-1 to positively effect branching 
morphogenesis.  Flt-1 is thought to modulate VEGF-A presentation to endothelial 
cells for proper vascular branching (A).  When Flt-1 is not present, we have 
observed defective sprout formation and migration (Chapter II) (B).  We propose a 
model in which flt-1 is secreted from endothelial cells, to potentially modulate a 
VEGF-A gradient, leading to increased sprout formation (C).  Filopodia, which 
express flk-1 and are extended from sprout tips, may act as sensors in an 
environment where VEGF-A presentation is important to properly regulate vascular 
sprout migration.  Improper spatial presentation of VEGF-A (mflt-1-expressing cells), 
may lead to perturbed ability of sprout tips to sense environment, leading to 
improper formation of vessel branches (D).
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CHAPTER IV 
 
ENDOTHELIAL CELL DIVISION OPERATES INDEPENDENTLY OF     
BRANCHING MORPHOGENESIS IN ES CELL-DERIVED VESSELS 
 
 
The work described in this chapter was done in conjunction with Kim Kallianos, an 
undergraduate student in the lab.  This work was the basis for Kim’s senior honors 
thesis. 
 
 
A.  Introduction 
 
 To understand how blood vessels develop, it is important to determine how 
the individual components of cell division and cell migration and sprouting 
(morphogenesis) are integrated.  During angiogenesis, cells must process and 
integrate extra-cellular signals to coordinate cell division, migration, and fusion of 
endothelial cells from existing vessels to form a branched vascular network, but how 
these signals are regulated and assimilated to produce a properly branched vascular 
network is unknown.   
The classic paradigm for the relationship of cell division and other cellular 
processes is that cells compartmentalize these components, so that dividing cells 
are not competent to differentiate or undergo non-division related morphogenesis 
(Zhu and Skoultchi, 2001).  One example of this can be found in the developing fly 
trachea, another tubular structure.  During tracheal development, the ectodermal 
cells that comprise the trachea undergo multiple rounds of cellular division first, and 
then the entire tracheal system will form and extend in the absence of any further 
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divisions (Metzger and Krasnow, 1999).  In contrast, development of the vertebrate 
vasculature is associated with simultaneous cell division, and the cells divide in the 
context of a vascular structure (Clark and Clark 1939).  Thus, during sprouting 
angiogenesis, cell division and morphogenesis occur concurrently.   
VEGF-A binds two high affinity receptors on endothelial cells, Flk-1 and Flt-1, 
and modulation of VEGF-A signaling by genetic deletion of either receptor affects 
endothelial cell division and morphogenesis (Fong et al., 1995; Kearney et al., 2002; 
Kearney et al., 2004; Shalaby et al., 1997).  There is evidence that suggests that 
different downstream VEGF-A signaling targets influence endothelial cell division 
and morphogenesis.  VEGF-A activation of the Flk-1 signaling pathway stimulates 
endothelial cell division through the Raf/MEK/ERK pathway, while endothelial cell 
migration is activated via the p38 pathway (Kroll and Waltenberger, 1997; Rousseau 
et al., 2000).  Also, the overall concentration of available VEGF-A is thought to 
modulate endothelial cell division, while VEGF distribution, is thought to modulate 
endothelial cell morphogenesis (Gerhardt et al., 2003; Kearney et al., 2002; Kearney 
et al., 2004; Ruhrberg et al., 2002). 
Work done in our lab suggests that morphogenetic signals may modulate cell 
division during angiogenesis in vitro and in vivo.  An example of this can be 
observed in ES cell-derived vessels, where endothelial cell division is increased in 
areas of active morphogenesis (Kearney et al., 2004).  Recent data from ES cell-
derived vessels and from rat retinas suggest that the plane of endothelial cell 
division is normally oriented perpendicular to the long axis of the vessel, which can 
promote vessel lengthening (Zeng et al., submitted).  However, cell division 
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orientation becomes randomized in a flt-1 mutant background, a mutation that leads 
to vessel dysmorphogenesis. Thus, there is suggestive evidence that cross-talk 
between the cell division component and the morphogenesis component travels 
from morphogenesis to cell division.  However, it has not yet been determined if the 
flow of cross-talk can occur in the opposite direction; that is, can the cell division 
pathway directly communicate with the morphogenesis pathway?  To test this, we 
have used a genetic approach to negatively modulate cell division in the vascular 
endothelium of ES cell-derived vessels, and to analyze subsequent effects on 
morphogenesis.   
Most eukaryotic cells proceed through an ordered series of events, 
constituting the cell cycle, during which the chromosomes are duplicated and one 
copy of each duplicated chromosome segregates into two daughter cells.  
Regulation of the cell cycle is critical for normal development.  Various cyclin-
dependent kinase (CDK)-cyclin complexes trigger progression through different 
stages of the eukaryotic cell cycle by phosphorylating specific target proteins.  Cells 
employ cyclin-dependent kinase inhibitors to inhibit the kinase activity of CDKs.  The 
p21 Cip/WAF1 family of CDKs is downstream of p53 activity and acts to inhibit Cdk4, 
6-cyclinD and Cdk2-cyclinE, thereby arresting the cell cycle during the G1 to S 
transition (Figure 16) (Dulic et al., 1994; el-Deiry et al., 1993; Gentilini et al., 1999; 
Kumeda et al., 1999; Schonthal et al., 1999).   
It has also been reported that mice expressing p21 specifically in hepatocytes 
results in a block in cell cycle progression, with no apoptosis observed (Wu et al., 
1996).  Furthermore, we have expressed p21 in Py-4-1 cells (endothelial cell line), 
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and observed no obvious cell death over several days (data not shown).  Thus, p21 
appears to be a good candidate for inducing ectopic endothelial cell growth 
modulation.  Our lab has also used the DNA replication inhibitor, mitomycin C, to 
treat day 6 flt-1 mutant cultures.  Flt-1 mutant cultures have an endothelial cell 
overgrowth defect, exhibited by in increase in vascular area; however, two days after 
mitomycin C treatment, a partial rescue of the vascular area is observed (Kearney et 
al., 2002).  However, the caveat exists that mitomycin C treatment has a pervasive 
effect on all cells in culture. Thus, a transgenic approach to achieve cell cycle 
modulation is required. 
To determine if inhibiting cell division has consequences on endothelial cell 
morphogenesis, the vascular-specific Tie-2 promoter was linked to a p21-GFP fusion 
transgene, and expressed in WT ES cell-derived vessels.  Our preliminary results 
indicate that a lack of cell division does not appear to affect the pattern of vessel 
branching in WT ES cell-derived vessels, suggesting that the cell division pathway 
does not directly communicate with the morphogenesis pathway. 
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B.  Materials and Methods 
ES cell culture and in vitro differentiation 
Wild-type (WT) ES cells containing a p21-GFP fusion transgene (gift from Dr. 
Neus Agell) under the transcriptional control of the Tie-2 promoter/intron enhancer 
element were maintained and differentiated as described previously (Bautch et al, 
96; Kearney and Bautch, 03).  Embryoid bodies (EBs) were plated onto either slide 
flasks (Nunc, Rochester, NY), or in wells of a 24-well tissue culture dish at day 3 of 
differentiation and cultured at 37oC in 5% CO2 until day 8, when cultures were fixed 
and analyzed.   
 
DNA constructs and electroporation 
 The Tie-2 promoter/intron enhancer (gift of Tomas Sato) was linked to a p21-
GFP fusion transgene.    The p21-GFP (GFP fused to N-terminus of human p21 
cDNA) transgene was first removed from pBluescript II KS+ using EcoRV and NotI.  
The Tie-2 expression vector containing a neomycin resistance cassette was next 
digested with SmaI and NotI, and the p21-GFP transgene was subsequently ligated 
to the Tie-2 expression vector to make Tie-2-p21-GFP-NeoR. 
Fifteen µg of linearized DNA was electroporated into 2 X 107 WT ES cells 
using a BioRad GenePulser II electroporator (250V/300µF; BioRad, Hurcules, CA.)  
Selection of WT ES cells was in 200 µg/mL geneticin.  After 12-14 days, Thirty WT 
drug-resistant transgenic ES clones containing Tie2-p21-GFP-Neo (designated at 
WT Tg Tie2-p21-GFP) were picked, expanded, and analyzed. 
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Antibody staining 
ES cultures at day 8 of differentiation were rinsed with phosphate-buffered 
saline (PBS) and fixed for 5 minutes in either ice-cold methanol-acetone (50:50) or 
4% paraformaldehyde.  Fixed cultures were reacted with rat anti-mouse PECAM at 
1:1000 (MEC 13.3; BD Pharmingen, San Diego, CA) or anti-mouse ICAM-2 at 1:500 
(BD Pharmingen, San Diego, CA), and donkey anti-rat immunoglobulin G (IgG; H+L) 
conjugated to TRITC at 1:100 (Jackson Immunoresearch, West Grove, PA) as 
described previously (Bautch et al., 2000).  Cultures were viewed and photographed 
with either an Olympus IX-50 inverted microscope (Melville, NY) outfitted with 
epifluorescence, or with a Leica inverted DMIRB microscope (Bannockburn, IL) and 
a Hamamatsu OrcaER CCD camera (McHenry ,IL). 
 
Quantitative image analysis  
To quantify the area labeled with PECAM antibody in differentiated ES 
cultures, fixed cultures were reacted with PECAM antibody, and photographed (10X) 
and analyzed as described (Kearney et al., 2002).  Percent PECAM area averages 
for each well were calculated, and the average of 4 wells for each ES clone was 
used to determine SD values.  Branch point analysis was done on fixed cultures 
reacted with PECAM antibody and photographed at 20x as described (Kearney et 
al., 2004).  The average branch point score from 8-12 pictures for each ES clone 
was used to determine SD values. 
Vessel diameter analysis was used to calculate the average diameter of 
vessels photographed using a 20x objective.  Measurements were taken from two 
 105
different subcategories of vessels: branch-to-branch vessels and branch-to-tip 
vessels.  The average diameter from three measurements of a vessel or vessel 
segment was calculated (measurements taken at each end of the vessel, and in the 
middle) for WT and WT Tg Tie2-p21-GFP vessels.   
 
RNA analysis 
For RT-PCR, total RNA was prepared using Trizol reagent (Invitrogen, Carlsbad, 
CA) according to the manufactures instructions.  Ten µg of total RNA was digested 
with DNase I (Promega, Madison, WI), and 2 µg of DNase-treated total RNA was in 
vitro transcribed with Superscript II reverse transcriptase (Invitrogen) in a total 
volume of 80 µl. 10 µl of the reaction was used for PCR experiments. Taq 
polymerase (Qiagen, Valencia, CA) was used to amplify cDNA using the following 
primer sets: (1st set; GFP-specific primers) forward 5’ 
GACGTAAACGGCCACAAGTT 3’; reverse 5’ TGCTCAGGTAGTGGTTGTCG 3’.  
(2nd set; p21-GFP-specific primers) forward 5’ CCGACCACTACCAGCAGAAC 3’; 
reverse 5’ AGACGAAGTTGCCCTCCAG 3’.  PCR reactions were performed for 3 
min at 95oC, followed by 30 cycles of 1 min at 94oC, 1 min at 60oC, and 1 min at 
72oC.  The PCR products were electrophoresed on a 3% agarose gel and detected 
by ethidium bromide staining. 
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C.  Results 
Selection of WT Tg Tie2-p21-GFP clones 
To directly assess the relationship between cell division and cell 
morphogenesis, we generated ES clones carrying p21-GFP fusion transgenes 
randomly integrated into the genome of WT ES cells.  The transgenes were linked to 
the Tie-2 promoter/enhancer because it results in expression of transgenes in 
developing blood vessels (C. Ellerstrom and V.L. Bautch, unpublished results).  After 
electroporation and selection, no visible GFP was apparent in any of the ES clones.  
Since GFP was not detectable, individual ES clones were picked at random for 
further analysis.  25 WT Tg Tie2-p21-GFP ES clones were picked and differentiated to day 
8, then processed for RT-PCR using GFP-specific primers (Fig. 17A and data not 
shown).  Next, primers specific for the p21-GFP fusion transgene were used for RT-
PCR to identify transgenic ES clones that produced a p21-GFP transcript (Fig. 17B). 
Transgenic ES clones #26, #27, #29, N5, and N10 were positive for the p21-GFP 
RNA via RT-PCR using either one or both primer sets, and were selected for further 
analysis.    
 
WT Tg Tie2-p21-GFP clones have a reduced vascular area 
 WT and WT Tg Tie2-p21-GFP clones (#26, #27, #29, N5, and N10) were 
differentiated to day 8 and labeled with PECAM-1 or ICAM-2 to visualize vascular 
morphology.  The p21-GFP transgenic clones contained less organized and 
fragmented vasculature, with an overall reduction of areas containing branched 
vascular networks compared to WT controls (Fig. 18A-B).  To quantify the degree of 
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reduced vascular area in the transgenic clones, we calculated the percentage of the 
culture that stains for PECAM-1, which approximates the amount of vasculature 
(Kearney et al., 2002).  WT cultures had between 15% and 22.8% PECAM+ area 
(Fig. 18C), and WT Tg Tie2-p21-GFP#26 and WT Tg Tie2-p21-GFP#27 cultures had percent 
PECAM areas that were not significantly different from WT controls. Clones N#26 
and N#27 also had phenotypes similar to that of WT cultures (Fig. 18C and data not 
shown).  WT Tg Tie2-p21-GFP#29, WT Tg Tie2-p21-GFP#N5, and WT Tg Tie2-p21-GFP#N10 clones, 
however, displayed a significant reduction in percent PECAM area compared to WT 
controls (Fig. 18: WT= 22.74% versus WT Tg Tie2-p21-GFP#29= 10.94% , WT Tg Tie2-p21-
GFP#N5= 8.87%; WT=15.3% versus WT Tg Tie2-p21-GFP#N10= 4.7%,  WT Tg Tie2-p21-GFP#N5= 
5.3%).  These results were confirmed after quantifying percent vascular area with a 
second vascular-specific marker, ICAM-2, for selected clones (Fig. 18D).  Thus, 
three of the five p21-GFP-expressing clones showed a decrease in vascular area. 
 
WT Tg Tie2-p21-GFP clones have normal vessel branching 
 To begin to understand the effects of a p21 transgene on vascular 
morphogenesis, we next quantified the number of vascular branches using a branch-
point assay.  Fixed samples of day 8 WT and WT Tg Tie2-p21-GFP (#26, #27, #29, and 
N5) cultures were labeled with PECAM to visualize vessels (Fig. 19A-F and data not 
shown).  Our results show that there is no significant difference in branch point 
scores between WT and any of the transgenic clones analyzed (Fig. 19G).  Thus, 
this data suggests that while expression of a p21-GFP transgene reduces the overall 
vascular area, it does not appear to influence vessel branching. 
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WT Tg Tie2-p21-GFP clones have smaller vessel diameters compared to WT vessels 
 Since there is a decrease in vascular area to go along with normal branching 
in the ES clones expressing the p21-GFP transgene, we hypothesized that the 
resultant vessels would have a smaller diameter than WT vessels.  Thus, PECAM-
stained samples of WT and two p21-GFP transgenic clones that showed reductions 
in percent vascular area (#N5 and #N10), but had a normal vessel branch score, 
were assayed for vessel diameter (Fig. 20A-C).  
To calculate vessel diameter, measurements were taken from two different 
categories of vessels: Branch-to-tip vessels; and branch-to-branch vessels.  Branch-
to-tip vessels included the length of vessel that extended from a branch point to the 
vessel tip.  Branch-to-branch vessels included the length of vessel that extended 
between two branch points.  Our data shows that WT Tg Tie2-p21-GFP clones (WT Tg Tie2-
p21-GFP#N5 and WT Tg Tie2-p21-GFP#N10) have significantly reduced vessel diameters in the 
branch-to-branch category compared to WT controls (Fig. 20D).  In the branch-to-tip 
category, although the average value in WT was higher than in the transgenic 
clones, there was no statistically significant difference between transgenic clones 
and WT in this category (Fig. 20D).  Thus, it appears that in the two clones analyzed 
with decreased vascular area, vessel lumens have decreased vessel diameters.  
However, vessel tips (sprouts), which normally have very thin vessels, do not have a 
significant change in vessel diameter. 
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D.  Discussion 
The work presented in this chapter suggests that the endothelial cell division 
pathway does not directly communicate with the morphogenesis pathway.  In an 
attempt to block the cell division pathway in endothelial cells, we have introduced a 
Tie-2-p21-GFP fusion transgene into WT ES cells.  Several experimental clones 
expressing the p21-GFP transgene had significant reduction in vascular area.  
However, despite the lack of vasculature, the amount of vascular branching found in 
these clones appears normal.  Moreover, further analysis revealed that two of these 
transgenic clones, WT Tg Tie2-p21-GFP#N5 and  WT Tg Tie2-p21-GFP#N10, have thinner vessels 
than controls.  Thus, this data, along with other results from our lab, suggest that 
signals do not directly travel from the cell division pathway to the cell morphogenesis 
pathway, but that communication travels from morphogenesis to cell division (Fig. 
21). 
 The vascular-specific promoter, Tie-2, which is expressed by endothelial 
precursors and by the endothelium of actively growing blood vessels in vivo (Dumont 
et al., 1992; Sato et al., 1993) and in our ES cell model, was used for endothelial-
specific expression of a p21-GFP fusion transgene.  The p21-GFP fusion protein has 
been shown to properly localize in the nucleus, and to inhibit cell proliferation in 
NIH3T3 cells as assessed by BrdU incorporation (Rodriguez-Vilarrupla et al., 2002).  
Thus, the cell cycle inhibitor p21, which inhibits cell cycle progression from G1 to S 
phase, was used to inhibit cell proliferation in developing blood vessels. 
While we have not formally shown that the p21-GFP transgene is inhibiting 
the cell cycle in our clones, we do have some evidence to suggest that the 
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phenotypes observed in the WT Tg Tie2-p21-GFP cultures are due to the effects of the 
p21 transgene.  First, we previously introduced the Tie-2-p21-GFP transgene into 
Py-4-1 cells (endothelial cell line).  These cells did not form colonies over a 6-8 day 
period; however, they continued to express GFP, suggesting that these cells were 
viable but unable to divide (data not shown).  Secondly, RT-PCR results indicate that 
the p21-GFP transgene is being transcribed into RNA in these clones (Fig. 17). 
Lastly, personal experience with many experiments requiring transgene 
electroporation into ES cells suggests that the phenotypes observed here; 
decreased vessel area and diameter, do not normally result from integration of 
transgenes into genomic DNA or clonal isolation.  Taken together, this evidence 
suggests that the phenotypes that we have observed in this study are most likely 
due to the effects of a p21 transgene. 
 After selection of resistant clones, GFP was not detectable in differentiating 
ES cell cultures.  GFP and p21 antibody experiments were performed 
unsuccessfully in an attempt to determine where the p21-GFP protein was localized.   
While we do see expression of the transgene RNA by RT-PCR, it remains a 
possibility that p21-GFP protein is not being produced in these clones.  RT-PCR 
results show modest levels of transgene expression, and our experience with the 
Tie-2 promoter has revealed it to have relatively weak transcriptional activity (C. 
Ellerstrom and V.L. Bautch, unpublished results).  The Tie-2 promoter was chosen 
because of its activity in endothelial cells during later stages of vascular 
development, thus allowing for the formation of stable ES cell colonies.  Thus, we 
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suggest that levels of p21 protein are made that elude detection but lead to a 
vascular phenotype.   
In the future it may behoove us to subject our transgenic clones to FACS 
analysis to determine endothelial cell numbers. This could then be followed by a cell 
cycle analysis to determine the degree of cell cycle inhibition.  Further evidence to 
implicate the p21-GFP transgene in inhibiting cell cycle progression would be to look 
at the activity of certain downstream targets of p21 in the p21-GFP-expressing 
clones.  For example, inhibition of cyclin-dependent kinase (cyclin E/Cdk2, cyclin 
D/Cdk4, and cyclin A/Cdk2) activity may be a good marker of p21 activity.  
Unphosphorylated retinoblastoma protein (Rb) may also be a good proxy for p21 
transgene activity.  While the expression of p21 did not induce any observable 
apoptosis in the hepatocytes of mice (Wu et al., 1996) or in our endothelial cell line 
(data not shown), it may be important to assay for cell apoptosis in our p21-GFP-
expressing clones.  This would help to confirm that the phenotypes observed are not 
due to cell death of p21-GFP-expressing cells. 
Our results show that there is a reduction of vascular area in many of the WT 
Tg Tie2-p21-GFP experimental clones compared to WT controls.  This was determined by 
calculating the percentage of PECAM and/or ICAM-2-stainined area within a culture.  
Previous work done in our lab using ICAM-2 labeling, along with FACS analysis with 
PECAM antibody on differentiating ES cultures has indicated that percent PECAM 
area analysis to be a good measure of endothelial cell numbers (Kearney et al., 
2002).  Of the five p21-GFP transgenic clones subjected to PECAM or ICAM-2 area 
analysis, three had a significant reduction of vascular area compared to WT controls 
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(Fig. 18).  While all five clones expressed the transgene via RT-PCR, it is not 
surprising that not all of the clones exhibited the same phenotype.  Work described 
in Chapter III illustrates how electroporation of transgenes into ES cells can result in 
different expression profiles from one clone to the next, and thus, different 
phenotypes.  Therefore, it may be important to carefully analyze the expression 
profiles of individual transgenic clones to better understand how p21 contributes to 
the phenotype of each clone. 
 To assay the potential affects of inhibiting cell proliferation on vascular 
morphogenesis, we compared branch point scores between WT and WT Tg Tie2-p21-
GFP experimental clones.  Vascular sprouting analysis done in our lab using time-
lapse movies of GFP-labeled vessels along with fixed culture analysis has shown 
that branch point analysis is a relevant measure of vascular sprout formation 
(Kearney et al., 2004).  Of the four p21-GFP transgenic clones subjected to branch 
point analysis, two (WT Tg Tie2-p21-GFP#N5 and WT Tg Tie2-p21-GFP#N10) showed reduced 
vascular area compared to controls (Fig. 19).  However, none of the four clones 
analyzed had a significantly different vascular branching score compared to controls.  
This data suggests that a potential decrease in the number of available endothelial 
cells via p21 does not influence vascular branching.   
 
Although vessel branching is normal in transgenic clones with decreased 
vascular area, these clones (WT Tg Tie2-p21-GFP#N5 and  WT Tg Tie2-p21-GFP#N10) have 
decreased vessel diameters compared to WT controls (Fig. 20), further suggesting 
that limiting cell numbers via p21 does not affect branching morphogenesis.   While 
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there was a significant difference in vessel diameter between WT and experimental 
clones WT Tg Tie2-p21-GFP#N5 and WT Tg Tie2-p21-GFP#N10 in the branch-to-branch category 
of vessels, there was not a significant difference when measuring the diameter of 
branch-to-tip vessels.  From time-lapse imaging of GFP-labeled vessels, we have 
evidence that on occasion, albeit rarely, the most distal cell of the sprout (tip cell) 
undergoes cell division.  However, in a study using retinal vessels, tip cells were 
never observed to divide (Gerhardt et al., 2003).  Thus, it seems that tip cells rarely, 
if ever, divide.  Therefore, it is possible that the reason for no significant difference in 
vessel diameter of branch-to-tip vessels between WT and p21-GFP transgenic 
cultures can be attributed to the idea that cell division in those regions of the 
vasculature is inherently less frequent, and that inhibiting cell division should not 
have a substantial effect on vessel thinning. 
The data reported here is consistent with a model in which the cell division 
compartment does not directly communicate with the morphogenesis compartment.  
Preliminary work done in our lab suggests, however, that morphogenesis may 
influence cell division.  Live imaging of cell division and sprouting angiogenesis in 
ES cell-derived vessels showed that cell divisions were not excluded from vascular 
sprouting areas, but in fact, were in most cases enriched in the sprouts and their 
vicinity, suggesting that sprout formation may stimulate cell division (Kearney et al., 
2004).  Furthermore, evidence suggests that the effects of the VEGF-A receptor flt-1 
on vascular sprout formation are independent of cell division (Kearney et al., 2004) 
(Chapter II).  Moreover, work done in ES cell cultures and in rat retinas shows that 
endothelial cell division orientation is normally oriented perpendicular to the long axis 
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of the vessel; however, this orientation is perturbed in a flt-1 mutant background, a 
mutation that also leads to vessel dysmorphogenesis (Zeng et al., submitted).  Thus, 
there is preliminary evidence that morphogenetic signals may modulate cell division 
during angiogenesis in vitro and in vivo (Fig. 21).  Activation of VEGF-A signaling 
can affect both endothelial cell division and morphogenesis, and modulation of 
VEGF signaling can regulate the rate of endothelial cell division (Kearney et al., 
2002; Kroll and Waltenberger, 1997).  We and others have also shown that VEGF-A 
can regulate cell migration and sprout formation (Kearney et al., 2004; Ruhrberg et 
al., 2002).  Thus, it is likely that the VEGF-A signaling pathway is involved in 
regulating the integration between the cell division and morphogenesis components.  
However, cross-talk between these two components probably occurs upon activation 
of targets down-stream of VEGF-A signaling.  It will be interesting to see exactly 
which downstream pathways allow for morphogenesis and cell division to 
communicate.  VEGF-A signaling can affect focal adhesion kinase (FAK) and Src, 
molecules involved in endothelial cell migration (Abedi and Zachary, 1997; Abu-
Ghazaleh et al., 2001; Rousseau et al., 2000).  Activation of the small GTPase Rho 
by VEGF-A/flk-1 has also been implicated in cell migration (van Nieuw Amerongen, 
Koolwijk et al. 2003), however, it is known that Rho also modulates the actin 
cytoskeleton and subsequent cell cycle progression (Mettouchi et al., 2001; Welsh et 
al., 2001).  Thus, the intersection for communication between morphogenesis and 
cell division may begin with this target.  Therefore, teasing out the different pathways 
will be the key to a better understanding of how these two compartments are 
integrated for proper blood vessel formation.
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Figure 16.  The cell cycle.  The cell cycle is divided into four major phases.  In 
replicating somatic cells, chromosomes are replicated during S (synthesis) phase.  
After progressing through the G2 (gap) phase, cells begin the process of mitosis (M-
phase).  Following mitosis, cycling cells enter G1 phase, the period before DNA 
synthesis is reinitiated in S-phase.  The cell cycle inhibitor, p21, is active during 
several points during the cell cycle, specifically at the G1ÆS transition.  Image taken 
from www.cancerline.com. 
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Figure 17.  WT Tg Tie2-p21-GFP clones express the p21-GFP fusion transgene.   
GFP RNA and p21-GFP fusion RNA was analyzed by RT-PCR.  Total RNA (2 µg) 
was isolated from wild-type (WT) and WT Tg Tie2-p21-GFP transgenic ES clones clones 
on day 8 of differentiation.  RNA was reverse transcribed, and resulting cDNAs were 
amplified by 30 PCR cycles using GFP primers (A), and primers specific to the p21-
GPF fusion construct (B, C).  DNA vector was used as positive control (+), while no 
template was used as a negative control (-). Transgenic clone numbers are indicated 
above images.
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Figure 18.  Quantitation of proliferation rescue.   
(A-B) Day 8 differentiated ES cultures reacted with ICAM-2 antibody to visualize 
vasculature.  WT (A) and WT Tg Tie2-p21-GFP#N5 (B) are 10x magnification.  (C-D) Day 8 
differentiated WT and WT Tg Tie2-p21-GFP transgenic clones were analyzed for PECAM+ 
(C) and ICAM-2+ (D) area as described (see Materials and Methods).  Clone 
numbers are indicated along x-axis.  *P<0.001, WT versus WT Tg Tie2-p21-GFP 
transgenic clones.  
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Figure 19.  WT Tg Tie2-p21-GFP transgenic clones and WT cultures have equivalent 
vascular branching.  (A-C) Day 8 differentiated ES cultures reacted with PECAM 
antibody to visualize branched vessels.  WT (A), WT Tg Tie2-p21-GFP#29 (B), and WT Tg 
Tie2-p21-GFP#N5 (C) are 20x magnification. Clone number is indicated in lower right of 
each panel.  (D) The average number of branch points per mm of vessel length was 
determined.  No p21-GFP transgenic clone had a branch score that was significantly 
different from WT. 
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Figure 20.  WT Tg Tie2-p21-GFP transgenic clones have reduced vessel diameters 
compared to WT vessels.  (A-C) Day 8 differentiated ES cultures reacted with 
PECAM antibody to visualize vasculature.  WT (A), WT Tg Tie2-p21-GFP#N5 (B), and WT 
Tg Tie2-p21-GFP#N10 (C) are 20x magnification. Clone number is indicated in lower right of 
each panel.  (D) The average diameter of vessel was determined in mm (average of 
three measurements/vessel length).  Measurements were made from two different 
vessel categories in both WT and p21-GFP transgenic clones: branch-to-branch; 
and branch-to-tip.  *P<0.001, WT versus WT Tg Tie2-p21-GFP transgenic clones. 
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Figure 21.  Model of communication between endothelial cell division pathway 
and morphogenesis pathway during blood vessel development.  Previous work 
done in our lab, in combination with the work presented here, suggests that the flow 
of communication does not go from the cell division pathway to the morphogenesis 
pathway, but that information travels from morphogenesis to cell division. 
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CHAPTER V 
GENERAL DISCUSSION 
  
In this dissertation, I present my work investigating the role of the VEGF-A 
receptor, flt-1, in embryonic vascular development.  Specifically, I have (in 
collaboration with another graduate student, Joseph Kearney) demonstrated that flt-
1 negatively modulates endothelial cell division of GFP-labeled ES cell-derived 
vessels (Chapter II).  This is consistent with in vivo and in vitro biochemical and 
genetic studies indicating that flt-1 functions to sequester VEGF-A and inhibit 
activation of the flk-1 pathway (Roberts et al., 2004) (reviews) (Olsson et al., 2006; 
Shibuya and Claesson-Welsh, 2006).  I have also, in collaboration with Joseph 
Kearney, demonstrated that flt-1 positively modulates vascular sprout formation 
(Chapter II).  Additionally, I have investigated the role of the flt-1 isoforms, 
membrane-bound flt-1 (mflt-1), and soluble flt-1 (sflt-1), in embryonic vascular 
development (Chapter III), and have demonstrated that both isoforms can modulate 
endothelial cell proliferation, while sflt-1 is more efficient than mflt-1in rescuing the 
flt-1-/- vascular morphogenesis defect.  These data support a model whereby flt-1 
must be secreted from endothelial cells to interact with sources of VEGF-A and 
modulate the presentation of VEGF-A to developing vessels for proper vessel 
branching morphogenesis. 
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Morphogenesis versus Cell Division.  Historically, endothelial cells have 
been observed to extend sprouts that migrate through the extracellular matrix of 
surrounding tissues (Clark and Clark, 1939).  Cells within sprouts can migrate and 
proliferate to establish a new vascular cord.  Furthermore, early studies suggested 
that there were separate migratory and proliferative functions within a developing 
vessel (Ausprunk and Folkman, 1977).  Our time-lapse imaging data shares some 
consistency with this idea.  The observation that since there is more endothelial cell 
division in the flt-1 mutant background, led to the formal possibility that aberrant cell 
division in flt-1-/- vessels somehow compromises vascular sprouting, leading to 
reduced sprout formation.  However, the observation that the sprouting defect 
persisted at day 8 (Chapter II, Fig. 2-3), when the rate of cell division in mutant 
vessels had returned to WT levels (Chapter II, Fig. 5), strongly suggests that the 
effect of flt-1 on sprout formation is independent of cell division.   
However, we did observe a novel relationship between dividing cells and 
migrating (sprouting) cells.   Dynamic image analysis of day 6 GFP-labeled ES cell-
derived vessels demonstrated that 78% of endothelial cell divisions occur within the 
walls of parent vessels (Primary Vessels), while 22% of cell divisions occur in the 
“sprout field” (Chapter II, table 1).  Image analysis of GFP-labeled vessels indicates 
that 97% of the vascular area consists of parent vessels, while only 3% of vascular 
area comprises the sprout field (N. C. K, V. L. B., unpublished results).  The finding 
that 22% of cell divisions occur in 3% of the vascular area indicates that divisions 
are enriched in vascular sprouts and their vicinity, and suggests that sprout 
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formation may stimulate endothelial cell division.  Preliminary work examining p21-
GFP-expressing ES cell-derived vessels suggests that limiting vascular cell numbers 
via p21 does not affect branching morphogenesis (Chapter IV).  Moreover, work 
done in ES cell cultures and in rat retinas shows that endothelial cell division 
orientation is normally oriented perpendicular to the long axis of the vessel; however, 
this orientation is perturbed in a flt-1 mutant background (Zeng et al., submitted), 
further suggesting that there may be communication between the morphogenesis 
compartment and cell division pathway.  Taken together, I believe that this work 
supports a model whereby morphogenesis stimulates endothelial cell division in 
vascular development.  There is precedent for this model in that tumor vessels also 
restrict cell divisions to sprout areas (Ausprunk and Folkman, 1977). 
 
Regulation of sprouting angiogenesis by flt-1.  Joe Kearney and I have 
demonstrated that the flt-1 mutation has an effect on vascular sprouting in vivo and 
in ES cell-derived vessels.  flt-1-/- vessels had reduced sprout formation and 
migration compared to wild-type vessels (Chapter II, Fig. 2-4), indicating that flt-1 
normally has a positive effect on these processes.  We hypothesized that in the 
absence of flt-1, there would be increased VEGF-A activation of flk-1, and 
subsequent increase in vascular sprout formation since VEGF-A promotes 
endothelial cell migration (review) (Olsson et al., 2006).  However, administration of 
exogenous VEGF-A inhibits sprouting of intersomitic vessels from the dorsal aorta in 
developing quail embryos (Drake and Little, 1995).  This is consistent with a model 
in which increased VEGF-A signaling inhibits vascular sprouting.  Therefore, flt-1 
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may have a role as a ligand sink to sequester VEGF-A and limit signaling via flk-1.  
While this is in agreement with a model in which flt-1 positively regulates vascular 
branching via antagonism of VEGF-A, intracellular signaling from the flt-1 receptor 
has long been thought to have a role in vascular development, possibly in regulating 
vascular branch formation.  In collaboration with Dr. Gefei Zeng, I have 
demonstrated that expression of a flt-1 isoform transgene lacking the cytoplasmic 
domain, in flt-1-/- vessels (flt-1-/-; Tg PECAM-mflt-1∆Cyt), rescues the flt-1 mutant vascular 
phenotype as efficiently as full-length mflt-1, suggesting that signaling via flt-1 is not 
required developmentally (Chapter III; Fig.  8, table 2).   This is consistent with a 
previous study where mice expressing cytoplasmic domain-deleted flt-1 survive and 
are healthy (Hiratsuka et al., 1998).  Taken together, this data indicates that the 
signaling function of flt-1 is dispensable for proper vascular development.   
 While we have showed the flt-1 is important in regulating branching 
morphogenesis, an understanding of the roles of the flt-1 isoforms, sflt-1 and mflt-1, 
has remained elusive in the field of developmental vascular biology.  While flt-1 
signaling is critical for macrophage/monocyte migration (Barleon et al., 1996; Clauss 
et al., 1996), as well as in certain circumstances in the adult (Luttun et al., 2002; 
Rafii et al., 2003), we and others have shown that it is not required developmentally.  
Thus, we hypothesized that sflt-1 may be the important isoform involved in vascular 
development. 
  
The introduction of sflt-1 and mflt-1 isoform transgenes into flt-1-/- vessels has 
demonstrated that sflt-1 is more efficient than mflt-1 in rescuing the flt-1-/- branching 
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defect (Chapter III).  One extension of the VEGF-A/flt-1 ligand sink model is that sflt-
1 aids in the formation of VEGF-A gradients in the extracellular matrix, and that 
proper modulation of VEGF-A correctly regulates vascular branching 
morphogenesis.  Consistent with this idea, previous results from our lab using 
western analysis of flt-1 protein suggests that sflt-1 protein is the dominant flt-1 
isoform (Frank W. DiPaola, Joseph B. Kearney, unpublished results).  In support of 
this data, other flt-1 antibody studies have shown that sflt-1 protein is expressed at 
higher levels than mflt-1 protein in vivo (Carmeliet et al., 2001; Hiratsuka et al., 
1998).  Furthermore, co-culture experiments utilizing wild-type and flt-1-/- ES cells 
indicates that flt-1 can act in a non-cell autonomous manner (Chapter II, Fig. 6), 
suggesting that sflt-1 is secreted from endothelial cells during vascular development.  
Likewise, analysis of VEGF-A isoform-selective mice provides evidence that a 
proper distribution of VEGF-A is required for correct regulation of vascular 
morphogenesis (Gerhardt et al., 2003; Ruhrberg et al., 2002; Stalmans et al., 2002).  
Thus, we propose a model where sflt-1 modulation of VEGF-A presentation to 
endothelial cells is important for efficient control of vascular branching.  I have 
demonstrated that sflt-1 can partially rescue the branching defect observed in flt-1-/- 
vessels (Chapter III, Fig. 8-9); however, there may be a requirement for mflt-1 to fully 
restore the branching score to wild-type levels.  Mflt-1, in combination with sflt-1, 
may be required to establish a complete flt-1 gradient.  Thus, introduction of both 
isoforms into flt-1-/- vessels may be necessary to completely rescue the flt-1 mutant 
phenotype. 
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 It may be possible to provide experimental evidence for gradients of VEGF-A 
and sflt-1 in vivo or in differentiated ES cultures by visualization of both VEGF-A and 
sflt-1 protein.  Attempts to carry out immunolocalization experiments using 
antibodies against VEGF-A or sflt-1 have proved to be unsuccessful in our 
laboratory.  Therefore, a dynamic image analysis approach could provide useful 
information.  The use of different fluorescent molecules, linked to VEGF-A, flt-1, or 
even flk-1, would enable us to dynamically visualize and study how these molecules 
regulate vascular development in vivo or in ES cell-derived vessels. 
 How may improper presentation of VEGF-A, which is thought to occur in flt-1-/- 
or flt-1-/-; Tg PECAM-mflt-1 vessels, lead to deregulated vascular sprout formation?  The 
migration of cells involves the assembly and disassembly of focal contacts between 
the actin cytoskeleton and the extracellular matrix (review) (Raftopoulou and Hall, 
2004).  Therefore, for cells to migrate, cells must be able to break existing focal 
contacts, while also forming new ones.  VEGF-A signaling through flk-1 promotes 
the migration of endothelial cells by the regulation of focal adhesion kinase (FAK) 
and Src, which stimulate focal adhesion formation and turnover (Abedi and Zachary, 
1995; Chou et al., 2002; Rousseau et al., 2000).  The activation of Src has been 
shown to inhibit the activity of RhoA, a major regulator of focal adhesion signaling 
and cell migration (Raftopoulou and Hall, 2004), while other studies have 
demonstrated that inappropriate stimulation or suppression of RhoA has an 
inhibitory effect on cell migration (Arthur et al., 2002).  Thus, inappropriate VEGF-A 
presentation and subsequent perturbed flk-1 activation, as seen in flt-1-/- or flt-1-/-; Tg 
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PECAM-mflt-1 vessels, may lead to increased levels of Src activation and inappropriate 
effects on RhoA , leading to a defect in proper vascular sprout formation. 
 We have observed sprout tips from flt-1-/- vessels to be more blunted, 
compared to the more tapered wild-type sprout tips (Chapter II, Fig. 4).  Closer 
inspection of flt-1-/- or flt-1-/-; Tg PECAM-mflt-1 vascular sprouts may reveal abnormal 
distribution of focal adhesion and actin-cytoskeleton regulators such as FAK, Src, 
and Rho family members.  Also, the generation of primary endothelial cell lines from 
flt-1-/- or flt-1-/-; Tg PECAM-mflt-1 differentiated ES cultures and subsequent analysis of 
focal adhesion signaling may help to determine if inappropriate RhoA-mediated focal 
adhesion signaling leads to improper vascular morphogenesis. 
 
Are endothelial cells divided into two distinct subpopulations?  Early 
studies by Ausprunk and Folkman (1977) demonstrated that endothelial cells have 
separate migratory and proliferative roles during embryonic angiogenesis.  More 
recent observation of vascular development has revealed a possibility that 
endothelial cells may exist as two different subpopulations (Gerhardt et al., 2003).  
These two distinct types of endothelial cells include the sprout tip endothelial cell 
and the main vessel body endothelial cell (hereafter termed “stalk cell”).  The sprout 
tip cell is the leading cell in a vascular sprout, while stalk cells include all of the cells 
behind a sprout tip cell.  We and others have observed several biochemical and cell 
biological differences between these two different groups of cells.  First, increased 
expression of flk-1 in sprout tip cells compared to stalk cells was observed by 
Gerhardt et al. (2003).  Secondly, while stalk cells do produce filopodial extensions, 
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we and others have observed increased numbers of filopodia emanating from sprout 
tip cells.  Filopodia carry out such functions as intercellular communication, cell 
migration, and cell adhesion (Wood and Martin, 2002). Thus, it is plausible to 
implicate sprout tip cells as sensors of positional information, which is provided in 
the form of VEGF-A presentation, to promote endothelial cell migration.  Therefore, 
these sensing sprout tip cells can potentially transmit positional information from the 
outside environment to the sprout tip cell and induce a vascular branching response.   
Aberrant distribution of VEGF-A has been associated with inappropriate filopodial 
extension and vascular branch formation (Ruhrberg et al., 2002; Stalmans et al., 
2002), suggesting a relationship between sprout tip cell filopodia and VEGF-A 
distribution.   
We and others have observed that while stalk cells divide frequently, sprout 
tip cells rarely, if ever, divide.  This, coupled with the assessment that stalk cells 
have decreased filopodia and flk-1 expression compared to sprout tip cells, suggests 
that stalk cells may have more of a proliferative role in vascular development, while 
sprout tip cells may have a primary role in branching morphogenesis.  Remarkably, 
these processes may be functionally independent since they affect two unique 
subpopulations of endothelial cells.  Stalk cell proliferation can proceed in the 
absence of sprout tip cell migration (Gerhardt et al., 2003), while we have observed 
sprout tip cell migration to occur in the absence of cell proliferation.   However, since 
we have suggestive evidence that sprout formation may stimulate cell division, there 
could be cross-talk in that direction.  Since morphogenesis and proliferation are 
mediated by flk-1, the two endothelial cell subpopulations may interpret the VEGF-
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A/flk-1 signals differently.  Modulation of VEGF-A presentation by a VEGF-A/flt-1 
gradient is interpreted differently in the sprout tip cell, whereas stalk cells may only 
interpret a concentration of VEGF-A (Gerhardt et al., 2003).  To better understand 
the role of the sprout tip cell and stalk cell, harvested endothelial cells could be 
grown in culture and induced to form vascular tubes.  Sources of VEGF-A could be 
placed at a distance from a newly formed vessel, so as to stimulate filopodia 
formation from the sprout tip cell.  If possible, microdissection and isolation of sprout 
tip cells, or possibly, cell sorting experiments selecting for cells with increased flk-1 
expression could be employed to isolate this endothelial cell subpopulation.  
Comparisons between these two cell populations can be carried out using 
microarray analysis to determine if there are genes that are differentially regulated in 
the sprout tip cell versus the stalk cell.   
 
Conclusion:  At the beginning of my studies, relatively little was known about 
how the flt-1 receptor affected vascular development.  My studies have 
demonstrated that flt-1 has a role in endothelial cell division and sprout formation 
during embryonic blood vessel formation.  In addition to these findings, I have 
helped to pioneer time-lapse imaging of vascular development in ES cell-derived 
vessels.  Furthermore, I have analyzed the roles of the flt-1 isoforms, sflt-1 and mflt-
1, and demonstrated that sflt-1 is more efficient than mflt-1 in regulating vascular 
branch formation; while sflt-1 and mflt-1 both have a role in regulating endothelial 
cell proliferation during embryonic vascular development.  Thus, flt-1 functions to 
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shape blood vessel morphology and is critical to the establishment of an intricate 
network of blood vessels during vertebrate embryogenesis. 
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